Abstract

Vertical Tabs

General Information

AC27 - Abstracts

The Abstract submissions are OPEN

(Deadline for submission: 1st October 2022)

The poster exhibition and the oral poster communication session are the mainstay of the annual European Association of Hospital Pharmacists (EAHP) Congress and only the best are selected!

The EAHP Scientific Committee (SC) encourages all hospital pharmacists, other health care professionals and scientists to submit their work for consideration leading to possible acceptance and display at the annual EAHP Congress. The SC strives to receive submissions of hospital pharmacy related initiatives from applicants in Europe and all over the world. All potential contributors are requested to carefully read and comply with the guidelines presented in this webpage. Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu. Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc... You can submit multiple abstracts. We also recommend that when submitting your Abstract, you use the same name and email address used for registering your participation to the Congress.

DEADLINES	ACTION
Saturday, 01 October 2022	Deadline for abstract submissions. Abstracts submitted after the deadline will not be accepted
Monday, 07 November 2022	Authors will be advised of their abstract status after the first review. Please check your spam if you did not receive the email.
Friday, 18 November 2022	Deadline for modifications due from abstract authors who were requested to make changes
Tuesday, 29 November 2022	Authors will be advised of their abstract status after review of modifications
Thursday, 01 December 2022	Deadline for Accepted Abstract to notify EAHP they do NOT want be included in the published ELHP (European Journal of Hospital Pharmacy)
Wednesday, 25 January 2023	Accepted Abstracts will receive an email with: Abstract Title and Text edit, new Abstract/Poster Number and QR Code
Wednesday, 01 February 2023	Accepted Abstract Authors to be registered and have confirmed attendance to the EAHP Congress 2023, in order to be included in the Printed Abstract Book
Wednesday, 01 March 2023	Accepted Abstract Posters to be sent to EAHP in PDF format for inclusion in order to be included on the Online Abstract Poster Wall
Wednesday, 01 March 2023	Accepted Abstract/Poster Authors to be registered and have confirmed attendance to the EAHP Congress 2023, to be guaranteed a Poster Panel at the Congress
Wednesday, 22 March 2023	Accepted Abstract/Posters to be delivered and hung in the EAHP Congress 2023 Poster Area (from 10.15 to 17.00)
Friday, 24 March 2023	Accepted Abstract/Posters to be removed from the EAHP Congress 2023 Poster Area (from 13.00 to 14.00)
Wednesday, 24 May 2023	Abstract/Posters present at the EAHP Congress 2023 to request a duplicate of the Poster Certificate (originaly sent by 01 April 2023)

The SC accepts two types of abstracts:

Scientific abstracts and
"Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here. For authors interested in submitting a GPI, please go here.

If you have any questions concerning the abstract submission process, please send an email to abstract[at]eahp[dot]eu.

Abstract Submissions and guidelines

The SC accepts two types of abstracts: scientific abstracts and "Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here.

Submit your Abstract here (Submissions close on 1 October 2022)

Submit your GPI here (Submissions close on 1 October 2022)

To check if your abstract meets the eligibility criteria for being a GPI or an abstract, answer all the following questions:

Table 1: The eligibility criteria for being a GPI or an abstract.

QUESTION	DEFINITION
1. Is your abstract relevant for hospital pharmacists?	Yes: Your abstract may be a scientific abstract or a GPI
1. Is your abstract relevant for hospital pharmacists?	No: Please do not submit your work to EAHP
2. Does your abstract describe a protocol or plan for a project not yet conducted?	Yes: Please do not submit your work to EAHP
	No: Your abstract may be a scientific abstract or a GPI
3. Is your abstract about the development and implementation of a pharmacy practice or a program in pharmacy education?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
4. Can other colleagues use your experience as the basis to introduce the same type of improvement in their settings by e.g. observing what you did in your setting?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
5. Does your abstract describe a project conducted as a scientific study using e.g. robust methodology?	Yes: Your abstract may be a scientific abstract
	No: Your abstract may be a GPI

For authors interested in submitting a GPI, please go here.

If you want to submit a scientific abstract, please check the instructions below.

ABSTRACT SUBMISSIONS AND GUIDELINES

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu. Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc... You can submit multiple abstracts. We also recommend that when submitting your Abstract, you use the same name and email address used for registering your participation to the Congress.

The EAHP Scientific Committee (SC) is looking for contributions with:

A high grade of relevance and/or innovation to the European community of Hospital Pharmacists,
A high impact on the future of hospital pharmacy practice, or
A high relevance regarding practice changes due to the investigated intervention.

SCOPE OF ABSTRACTS AND TOPIC GROUPS

We encourage the submission of abstracts from all disciplines of hospital pharmacy or related areas. The major categories and examples of topics are illustrated in the table below. The topics are not meant to represent a complete and exclusive list, but examples only that guide authors to select the most appropriate topic groups during the submission process.

Table 2: Categories for abstract submission with examples.

CATEGORY	EXAMPLES OF TOPICS
Section 1: Introductory Statements and Governance	Management theories, human resources, training requirements, financing, resource optimization, staffing, organisation, working environment, medicines management policies, drug & therapeutics committees, communication technology (telepharmacy, eHealth), national standards of hospital pharmacy services, pharmacoeconomics, health technology assessment
Section 2: Selection, Procurement and Distribution	Procurement processes, logistics, storage conditions, ordering systems, drug distribution technology (e.g., bar code scanning, electronic cabinets, dose dispensing), home delivery, supply chain management, medicines shortages, policy for medicines brought into the hospital by patients, preparation conditions, dispensing conditions, distribution conditions, disposal of medicines, medicines formulary systems, drug use evaluations
Section 3: Production and Compounding	Production technology, use of suitable commercially available pharmaceutical equivalents, risk assessment prior to production, formulation, quality control, best practice quality requirements, procedures for reconstitution or mixing of medicines, stability studies
Section 4: Clinical Pharmacy Services	Multidisciplinary therapeutic decision-making, quality improvement interventions, adherence, seamless care between and within healthcare settings, monitoring medication changes, service evaluation, service implementation, outcome evaluation, medicines reconciliation, medication history, prescription review, medication management review, medication appropriateness, drug-related problems, patient education, career education, health care professional education, patient knowledge, therapeutic drug monitoring, interactions, clinical pharmacokinetics, drug information and pharmacotherapy, nutrition support
Section 5: Patient Safety and Quality Assurance	Medication errors, adverse drug events, pharmacovigilance, medication error reporting, root cause analysis, high-risk medicines, patient safety programmes, risk minimization procedures, computerised decision support, safe transcription steps, accurate recording of allergy etc., quality and safety procedures, safe medicines use (preparation and administration), labelling, quality assurance, traceability, drug efficacy/safety evaluations
Section 6: Education and Research	Development of curricula, participation in European-wide competency frameworks (e.g., for initial post graduate education and training in hospital pharmacy), research methods, publication skills, pharmacy practice research, pharmacoepidemiology, protocols

IMPORTANT ITEMS TO CONSIDER BEFORE WRITING YOUR ABSTRACT

We kindly invite all applicants to carefully consider the following before submitting your abstract:

The prerequisite for a good abstract is a well-conducted study with clear study aims and methodology.
The purpose of the study should be understandable and should allow the reader to follow what has been done at a glance.
The interventions and relevant outcomes should be clearly defined.
The authors are strongly requested, prior to submission, to see what is published in their relevant field and reflect on the added value of their work (e.g. if they present data of national or even local peculiarities).
Before writing the abstract, clarify for yourself what is the new evidence you want to present and consider why colleagues should be interested in your study.

ABSTRACT STRUCTURE

Abstracts must be structured and written in five paragraphs: (1) Background and importance, (2) Aim and objectives, (3) Materials and methods, (4) Results, (5) Conclusion and relevance.

This structure of an EAHP congress abstract has to be strictly adhered to. The online abstract submission will guide you through this process. Abstracts are limited to no more than 350 words (or less if you use graphs or tables) and must be typed in English. The online submission system does not allow you to enter abstracts above this limit.

A blinded approach is used during the abstract review process, so it is recommended that the institution name and/or country name are NOT indicated in the abstract title and text. Contact data will not be displayed during the review process. This process is meant to ensure that the reviews are conducted in the most ethical and professional way possible.

Title: The title of the abstract must be strictly coherent with the data included in the abstract. Do not use abbreviations. If you are submitting a case report, the area of focus and "case report" should appear in the title.
Contact data: The name of every author, preceded by initials, and the name of the presenting author underlined and entered as instructed via the online submission process. Omit degrees, titles or institutional appointments. Then, insert the institution, city, country where the study took place or the case occurred, as well as the email address of the presenting author.
(1) Background and importance: The background sets the frame of your study. To set the scene you must answer the following questions: What is already known about this topic? what are the unmet needs which brought you to conduct this study? To answer those questions, you have to do a literature search to identify whether other observations in this field are already published. You should present the problem you want to focus on and highlight why the answer to the problem is important. For case reports briefly summarize why this case is unique with medical literature references.
(2) Aim and objectives: State the aim of the study. This very clear and concise text should state: What did you investigate and among whom? If you present a case report give patient information regarding the main concerns and symptoms of the patient in this section. Add medical, family, and psychosocial history including genetic information if applicable and needed. Relevant past interventions and their outcomes should also be reported here.
(3) Materials and methods: Describe the method, facilities (e.g. equipment/statistics, models), design, setting and participants and interventions being used. Please describe the intervention and which outcome measures were used, when applicable. If you do a literature review or a meta-analysis you have to give information regarding the data sources and the study selection criteria. For case reports relevant physical examination (PE) and other clinical findings should be reported in this section. Also the timeline of the case with relevant data from this episode of care organized as a timeline could be important. In some cases diagnostics and prognostic characteristics should be given when applicable. Please present therapeutic Interventions in this section.
(4) Results: Present the necessary data in a way that it is easy to understand. There is no discussion of the results in this part. For case reports clinician- and patient-assessed outcomes when appropriate should be given here. Please refer also to important follow-up diagnostic and other test results. Intervention adherence and tolerability (how was this assessed?) besides adverse and unanticipated events should be reported.
(5) Conclusion and relevance: Discuss your results and compare to literature data if available. Are other observations in this field already published and relevant to be mentioned? Based on your results, what are the answers to the problem you focused on? What are the new findings? What are the implications for practice and research? For case reports, please present strengths and limitations in your approach to this case. Please discuss the relevant medical literature and the rationale for your conclusions. You must present the primary "take-away" lessons from this case report.
References and/or acknowledgements: These may be given at the end of the abstract.

Please click here to download the abstract structure template which can give you an idea of an abstract structure before the online submission. Please note that only submitted online abstracts will be reviewed.

We advise authors to use scientifically common principles in abstract writing.

Abbreviations may be used only if they are defined (spelled out in full text at first mention, followed by abbreviation in parentheses). Only general standard abbreviations for e.g. millilitres, seconds, and moles may be used without explanation.
Don't use excessive decimals e.g. a person might weigh 70,237 kg at a given moment, but only 70 kg should be mentioned.
References should be limited to a minimum, unless they are important for understanding methods, background or conclusions drawn. References should be added in a special field during the abstract submission, which is optional for use and not mandatory. Comprehensive bibliography can be displayed on the poster.
The authors are encouraged to submit well-edited abstracts and avoid submission of negligent work.

THE SUBMISSION PROCESS

Please consider the selection of the appropriate topic group before submission and compare with the examples prior to submission (Table 2). The topics are directly related to the EAHP statements.
For every abstract there must be 3-5 keywords selected by the authors. These are used for indexing purposes and have to be strictly in line with the content of the abstract.
You can only add 1 presenting author and up to 10 co-authors.
You can submit multiple abstracts.

THE REVIEW PROCESS

Each abstract is read, assessed and scored independently by two members of the SC and considered from two perspectives: the scientific content and the practical value of the submission.
In case of divergence between the two reviewers, the full SC discusses the submission in plenum and comes to a view whether to accept the abstract or not.
You will be notified in a timely manner as to the outcomes of the review process. You may be asked to revise your abstract and re-submit it.
All accepted abstracts will be allocated a spot for display at the congress.
The SC selects outstanding abstracts for poster walks and poster prize competition. Only those abstracts that are considered to have a high grade of relevance, innovation and added value in a well-written form are eligible for winning the poster prize.

SPECIFICS REGARDING STUDY TYPES AND METHODOLOGY

Particular attention is given to those abstracts that report scientifically valid results with appropriate study methodology giving the type of study design, interventions and outcomes. Outcomes could comprise either direct patient benefit, economical or clinical outcomes, or a combination of these.
Quantitative studies should include at least 30 patients.
Case Reports of a single or of a few patients will be accepted only if they include original and new data, that is not as yet published in literature. Please find below more information.
Case reports of ADRs will only be accepted if they present some kind of causality or probability assessment (e.g. Naranjo algorithm)
Everyday clinical practice studies are of interest if effectiveness is reported in an adequately chosen size of study population, which is in line with the prevalence of the disease studied.
New drug interactions not already described in the literature are encouraged to be reported but should come with a possible mechanism or explanation.If interventions of improvements processes are reported, please always report baseline values or data regarding the situation prior to the intervention as well. Otherwise comparison is not scientifically valid and therefore of limited value and validity.
Abstracts reporting purely lab sciences or associated sciences to pharmacy (e.g. microbiology, biology, chemistry etc.) are only accepted if the implications of these basic study findings to hospital pharmacy practice are made clear by the authors.
Drug Usage Evaluation (DUE) will only be considered if data of at least 30 patients are reported.
Authors planning to perform and report the results of a DUE are referred to relevant guidelines (e.g. those from American Society of Health-system Pharmacists).

EAHP welcomes well-described reports of cases that include the following:

Unreported or unusual side effects or adverse interactions involving medications.
Unexpected or unusual presentations of a disease.
New associations or variations in disease processes.
Presentations, diagnoses and/or management of new and emerging diseases.
An unexpected association between diseases or symptoms.
An unexpected event in the course of observing or treating a patient.
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

Abstracts of case reports submited to the SC of EAHP with the aim to present a poster at the EAHP Congress should make a contribution to medical knowledge and must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches. EAHP will not consider case reports describing preventive or therapeutic interventions, as these generally require stronger evidence.

Case reports should be writen in the same way like the other abstracts, meaning you have to use the same template.

REASONS FOR REJECTION

Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

This practice is well established in many countries.
This abstract is not relevant to Hospital Pharmacy.
The committee did not understand the abstract either due to English use or other reasons.
Quantitative studies should usually include at least 30 participants.
The abstract does not follow the given structure.
The conclusion does not cover the aim of the study.
Insufficient data was included to support your conclusions.
An inappropriate or weak study methodology was used.
The abstract is not presenting a study with a defined aim, a described method to obtain results, presentation of the obtained results and/or a conclusion based on these findings.
The abstract may be better suited as a GPI. Please resubmit using the appropriate format.
This topic has already been studied and published several times.
If a same author or a same group of authors has submitted the same abstract several times by mistake, they should send an email to the EAHP office to inform them and delete the duplicated abstracts. Otherwise, the judges will reject all abstracts.
If a same abstract has been submitted by its author(s) both as a Good Practice Initiative and as an abstract, the judges will reject both abstracts.
Other

RECOMMENDATIONS

Prior to conducting your study, reflect on the appropriate methodology and the number of patients (e.g. power analysis) that is necessary for this study design. Your study must include at least 30 patients to be accepted.
Ask other colleagues who are not involved in the study if the abstract is understandable and your proposed message is conveyed.
Consider the coherence of the abstract. If not coherent, please strongly consider rewriting your abstract.
The conclusion should be limited to statements that directly arise from the results presented. General statements without reflection of results or not in line with the aim of the study have to be avoided, as this is a common reason for abstract rejection.
The word count has to be adhered to. Be aware, that this is an abstract. The purpose of an abstract is to report clear, concise and relevant scientific results. Additional data, which are not ultimately needed for understanding, can be shown in the final poster.
Please avoid formatting of abstracts, don't use bold type, and ensure that at the final checking stage that any special characters or symbols used are displayed correctly.
Abstracts reporting vague or unclear interventions and/or irrelevant outcomes will be rejected.

DISCLAIMER

While every effort is made by publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned.

Accordingly, the publishers and the European Association of Hospital Pharmacists (EAHP), the editorial committee and their respective employees, officers and agents, accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

The author is responsible for obtaining the permission and licenses used to complete his/her study. Please note that EAHP cannot be held responsible in case an author disrespects his/her obligation to obtain the permission and licenses.

Please click here to read the author licence from BMJ.

IMPORTANT: The abstracts that were rejected last year CANNOT BE RESUBMITTED again unless major modifications have been made. Should the authors not follow this rule, they will be banned from the submission process for the following EAHP congresses.

Good luck to all!

The EAHP Scientific Committee

Poster guidelines

ABSTRACT POSTER GUIDELINES

The Registration of the Abstract/Poster Submitting Author to the EAHP Congress 2023 must be finalized by 01 March 2023. Passed this deadline, no poster panel will be provided at the Congress.
The PDF Version of the Poster must be sent to abstract[at]eahp[dot]eu by 01 March 2023

SIZE:

841mm wide x 1189 mm high (A0) - portrait format (posters may not be smaller or larger than this size).

ASSISTANCE PROVIDED AT CONGRESS CENTRE

A poster panel on which to hang posters
A number for each poster board: this number indicates your assigned display station and also corresponds to the abstract number
Mounting materials, including double sided adhesive tape. Note that the use of drawing pins will NOT be allowed
Staff to advise during poster mounting

THE FOLLOWING COMPONENTS SHOULD BE INCLUDED AND USED AS HEADING WHERE APPROPRIATE

Title
Contact data
Background and Importance
Aim and Objectives
Materials and Methods
Results
Conclusion and Relevance
References and/or Acknowledgements

IT IS OFTEN USEFUL TO HAVE A SUMMARISED VERSION OF THE POSTER TO HAND TO INTERESTED READERS

You should also provide a notepad so that interested readers can leave their contact addresses, and a drop-box in which they can leave business cards or envelopes.

DESIGNING THE POSTER

Remember that viewers should be able to grasp the meaning of the poster without listening to an explanation or reading a report. To assist in this:

Communicate the message simply
Do not clutter the poster with too much detail
Only use materials that can be mounted on the poster board (plus handouts)
Use title lettering at least 2.5 cm high with text lettering at least 8 mm high and 0.7 mm thick. Test readability from 1 m or more away.
Use pie charts, histograms, graphs, tables, clip art, drawings, symbols and photos to illustrate key points. Use colour effectively in these and make them simple, rather than complex.
Design the poster to be read from left to right and top to bottom
Where possible, use one-line statements or bullet phrases to highlight key points, rather than full sentences (this list is set off by bullet points)
Use bold face type for headings and sub-headings
Proof-read the poster carefully. Ask a person independent of the project to review the text for clarity, organisation and brevity
Bring white correction tape or fluid and black felt tip pen to the meeting to correct errors or scratches

POSTER CERTIFICATES

Poster certificates for the presented posters will be sent to the authors by email within 15 days after the Congress. The duplicates can be provided by the author's request within 60 days after the last Congress. Please note that in case of loss of your poster certificates, the certificate duplicates of the last EAHP congress as well as any other previous EAHP congresses certificates will not be provided after the deadline of 60 days (24 May 2023).

POSTER PDFs FOR WEB SITE

Authors should send a pdf of their poster to abstract[at]eahp[dot]eu for inclusion on the EAHP web site following the congress. Deadline for receipt of your poster pdf is 01 March 2023.

DURING THE CONGRESS

The deadline to deliver and hang your poster at the Congress is Wednesday, 22 March 2023 from 10.15 to 17.00. Please note that there will be no access to the poster area to hang your posters before the indicated time. Please go to the poster area and check-in with the hostesses on duty to find out where and how to hang your poster. Note that all posters will be hung according to the Sections of the European Statements of Hospital Pharmacy and ATC code.

Presenters are expected to be present at their poster during 2 coffee breaks:

Thursday 23 March 2023, from 10.30 to 11.00
Friday 24 March 2023, from 10.30 to 11.30

DISCIPLINARY ACTION

If an author is unable to present his poster during the congress, he absolutely needs to notify the EAHP by sending an email to abstract[at]eahp[dot]eu. If same situation happens 3 years in a row, the EAHP reserves the right to reject any other abstracts submitted by the same author for future congresses. In addition, should the author not insure that their poster is hung during the congress either by the author or a colleague, the abstract will be removed from the online version of the abstract book.

Poster prize winners

ENCOURAGEMENT PRIZE FOR INVESTIGATORS

The best abstracts/posters (up to 12 award nominees) – with regards to aspects like originality, scientific quality and practical applicability – will be awarded with 3 prizes amounting EURO 750, EURO 500 and EURO 250.

Please be aware that the judges reserve the right not to award prizes if there are no clear winners.

Award nominees will be requested to give an oral presentation, taking place in different dates and times throughout the congress.

2023 award nominee oral presentations

TBC

Oral presentations are to consist of 5 minutes for presentation and 2 minutes for questions and answers. Poster prize nominees should disclose whether their work or comparable/similar work was submitted at an earlier International conference or somewhere else. More details will be sent to the authors by email. The winners will be announced at the closing ceremony on 24 March 2023.

Check the posters of past Congress winners below.

The Scientific Committee also choose up to 18 abstracts for the Poster walk. These abstracts will be highlighted in the online poster area in the congress platform and will include a recorded video of their presentation so you can watch their presentation at any time!

2022 Poster prize Winners (click on the title to download the poster)

1st Prize

IMPLEMENTATION OF AN INTERPROFESSIONAL PREOPERATIVE MEDICATION MANAGEMENT PROGRAMME IN CARDIAC SURGERY: A PRE–POST QUALITY IMPROVEMENT STUDY

Benedict Morath

2nd Prize

SELECTION OF CLINICAL RULES FOR THE SCREENING OF HIGH-RISK SITUATIONS IN PAEDIATRIC MEDICINE

Christian Skalafouris

3rd Prize

POSITIVE IMPACT OF AN IMPLEMENTED WARD PHARMACIST IN A MULTIPROFESSIONAL CANCER CARE TEAM IN GERMANY

Svenja Dierkes

2021 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Tessa Jaspers: EFFECT OF A MULTIFACETED CLINICAL DECISION SUPPORT INTERVENTION ON ADHERENCE TO THROMBOPROPHYLAXIS GUIDELINES IN NON-SURGICAL PATIENTS

2^nd Prize - Trine Andersen: A SCREENING MODEL TO IDENTIFY ELDERLY POLYPHARMACY PATIENTS THAT MAY BENEFIT FROM PHARMACIST LED MEDICATION REVIEW DURING HOSPITAL ADMISSION

3^rd Prize - Stefanie Sauer : USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY

2020 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Ulrika Gillespie: FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST

2^nd Prize - Ana Idoate: COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS

3^rd Prize - Charlotte Quintens: UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM?

2019 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Meshal Alshakrah: DETERMINING THE NECESSARY COMPONENTS OF A PHARMACEUTICAL CARE COMPLEXITY SCREENING TOOL: AN E-DELPHI STUDY

2^nd Prize - Antonella Tonna: ENCOURAGING THE RESPONSIBLE USE OF ANTIBIOTICS: AWARENESS AND UNDERSTANDING AMONG A UNIVERSITY STUDENT POPULATION OF A COMMUNITY PHARMACY PUBLIC HEALTH CAMPAIGN IN SCOTLAND

3^rd Prize - Rana Al Adawi (the abstract was presented by Antonella Tonna): A SYSTEMATIC REVIEW OF PHARMACIST INPUT IN THE SCREENING, MANAGEMENT AND PREVENTION OF METABOLIC SYNDROME

Online abstract poster walks

Please find below the online abstract Poster Walks of the last EAHP Congresses.

Please select the desired annual Congress to view the posters presented in the different topic categories.

26th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-01	The appropriateness review FOR HOSPITAL MEDICATION ORDERS IN FINLAND
	NP-02	Usage of falls-risk-increasing drugs among patients with high risk of falls in the nursing ward of Tartu University Hospital
	NP-03	From basic to advanced computerized IV to oral switch for paracetamol and antibiotics: an interrupted time series analysis
	NP-04	MONITORING OF GRAM-NEGATIVE (G-) MULTIDRUG RESISTANT (MDR) PATIENS AT POLICLINICO UMBERTO I OF ROME WITH THE AIM OF CONTROLLING HEALTHCARE ASSOCIATED INFECTIONS, COUNTERACTING THE PHENOMENON OF ANTIMICROBIAL RESISTANCE AND...
	NP-05	INTRAVESICAL EPIRUBICIN ADMINISTRATION IN A UROLOGY DEPARTMENT
	NP-06	RELATIONSHIP BETWEEN SERUM VEDOLIZUMAB CONCENTRATIONS IN INDUCTION PHASE AND EARLY AND SUSTAINED RESPONSE ON PATIENTS WITH ULCERATIVE COLITIS
	NP-08	Integrating pharmacogenetic information into medication reviews – an interprofessional challenge

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-003	IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS
	1ISG-004	ASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA
	1ISG-006	ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER
	1ISG-007	ECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL?
	1ISG-008	OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA
	1ISG-009	IMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY
	1ISG-012	ECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB
	1ISG-013	Users’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	HOW CAN WE BEST MANAGE SUPPLY SHORTAGES OF EXCLUSIVELY HUMAN MOLECULES FOR SUBSTITUTION ? THE EXAMPLE OF IMMUNOGLOBULINS
	2SPD-003	TELEPHARMACY IN ONCO-HEMATOLOGIC PATIENTS: A SEVEN MONTH EXPERIENCE
	2SPD-005	SIGNIFICANT DISCONTINUATION RATES IN PATIENTS INITIATING OR SWITCHING FROM CT-P13: A RETROSPECTIVE COHORT STUDY IN A UNIVERSITY HOSPITAL
	2SPD-006	DEVELOPMENT OF A PRIORITATION PROTOCOL FOR THE USE OF IMMUNOGLBULINS IN VIEW OF THE GLOBAL SUPPLY PROBLEM
	2SPD-008	NETWORK META-ANALYSIS OF IMMUNOTHERAPIES IN UNTREATED ADVANCED OR METASTARIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
	2SPD-011	RIVAROXABAN VERSUS ENOXAPARIN IN TRAUMATOLOGY: A PHARMACO-ECONOMIC STUDY
	2SPD-012	IMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY IN REAL LIFE
	2SPD-013	INCREASE IN HEALTHCARE COSTS WITH FIDAXOMICIN INSTEAD OF VANCOMYCINFOR CLOSTRIDIUM DIFFICLIE TREATMENT
	2SPD-014	APPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE
	2SPD-015	LOGISTICS AUTOMATION AND PROCESS REENGINEERING: IMPACT ON INTER-HOSPITAL LOAN MANAGEMENT
	2SPD-016	APPLICATION OF FAILURE MODE AND EFFECT ANALYSIS TO IMPROVE CYTOSTATIC DRUG STOCK MANAGEMENT
	2SPD-017	ANALYSIS AND MONITORING OF THE WORKLOAD AND FINANCIAL BURDEN OF DISPENSING HIGHCOST MEDICINES WITH ITEM-BASED REIMBURSEMENT IN HUNGARIAN HOSPITAL PHARMACIES
	2SPD-019	INVENTORY MANAGEMENT DURING THE COVID-19 PANDEMIC: OUR CASE FOR THE THIRD WAVE
	2SPD-020	INTRODUCTION OF A NEW PRESENTATION OF HYALURONIC ACID FOR INTRAARTICULAR INFILTRATION
	2SPD-021	ASSESSMENT OF FORECAST ACCURACY FOR CONTRACTUAL PURCHASES
	2SPD-022	RELEVANCE OF UNIVERSAL KIT COMPOSITION AND ECONOMIC VALUE OF NON-USED MEDICAL DEVICES
	2SPD-023	CHOOSING THE RIGHT FORECASTING METHOD: WHICH PRACTICE IS BEST FOR OUR CASE?
	2SPD-024	RETROSPECTIVE EVALUATION OF THE SAFETY STOCK LEVEL DETERMINED FOR THE PANDEMIC IN TERMS OF SERVICE LEVEL
	2SPD-025	ACALABRUTINIB + OBINUTUZUMAB VERSUS IBRUTINIB + OBINUTUZUMAB AS FIRST LINEIN CHRONIC LYMPHOCYTIC LEUKEMIA
	2SPD-027	Medication storage temperatures inside emergency vehicles A pilot study in a temperate climate country
	2SPD-029	STABILITY OF NIVOLUMAB SOLUTIONS AFTER TRANSPORT THROUGH PNEUMATIC TUBE SYSTEMS
	2SPD-030	How to assess the impact of medicines shortages in the European Union?
	2SPD-031	THE ECONOMIC IMPACT OF ANTIMICROBIAL SHORTAGES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES
	2SPD-032	DRUG EXCHANGE NETWORK
	2SPD-033	Making the case for Prefilled Syringes (PFS): Development and utilisation of an economic model
	2SPD-034	METHODOLOGICAL ANALYSIS OF PHARMACOECONOMIC STUDIES IN CAR-T: A SYSTEMATIC REVIEW
	2SPD-035	COST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	CHOLESTEROL 2%/SIMVASTATIN 1% OINTMENT FOR THE TREATMENT OF POROKERATOSIS PTYCHOTROPICA: A CASE REPORT
	3PC-002	GLASS AMPOULES AND DRUG FILTRATION: ¿HOW MUCH DO WE KNOW ABOUT IT?
	3PC-003	SODIUM THIOSULPHATE GEL 25% FOR THE TREATMENT OF CALCIPHYLAXIS
	3PC-004	INSULIN EYE DROP FORMULATION: EFFECTIVENESS, SAFETY AND PATIENT SATISFACTION
	3PC-005	SELECTION OF AN OSMOLARITY VALIDATION MODEL FOR NOMINATIVE PARENTERAL NUTRITION
	3PC-006	EVALUATION OF PARENTERAL NUTRITION COMPOUNDING THROUGH A CHECKLIST
	3PC-008	TIMES AND ERRORS FOR DISPENSING NARCOTICS DRUGS IN AUTOMATED SYSTEM VERSUS MANUAL SYSTEM
	3PC-009	STANOZOLOL RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) QUANTIFICATION METHOD FOR QUALITY CONTROL
	3PC-010	Assessment of Chemfort (OnGuard, US) Syringe Adaptor Lock Fitted With Luer Lock Syringes to Container Integrity Standards (NHS, UK) Supporting Dose Banding of Cytotoxic Drugs
	3PC-011	STUDY OF THE CONTAINERCONTENT INTERACTION BETWEEN ETOPOPHOS POLYVINYL CHLORIDE (PVC) PERFUSION
	3PC-012	IMPACT OF PRELIMINARY WIPING OF EQUIPMENT INTRODUCED INTO A CLEANROOM ON THE CONTROL OF THE ENVIRONMENT
	3PC-013	PHARMACEUTICAL COMPOUNDING IN PAEDIATRIC PATCH TESTING: ARE WE SURE ABOUT THE ACTUAL ACTIVE INGREDIENT CONCENTRATION?
	3PC-014	EVALUATION OF THE MICROBIOLOGICAL QUALITY OF NONSTERILE DRUGS PREPARED IN A HOSPITAL PHARMACY
	3PC-016	VANCOMYCIN EYE DROPS AT 50 MG/ML : PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS
	3PC-017	Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days
	3PC-018	COMPATIBILITY AND 30-DAY STABILITY OF FOUR INTRAVENOUS MIXTURES FOR MULTIMODAL ANALGESIA
	3PC-019	EVALUATION OF THE IMPACT OF MACHINE-AIDED DEBLISTERING IN UNIT DOSE BLISTER PRODUCTION ON THE FUNCTIONALITY OF TABLET COATING
	3PC-020	CHEMICAL STABILITY AND PHYSICAL COMPATIBILITY OF INSULIN EYE DROPS USED IN CLINICAL PRACTICE
	3PC-021	DESIGN AND ELABORATION OF METRONIDAZOLE 1% TOPICAL SOLUTION FOR TREATMENT OF ULCERS INFECTED BY ANAEROBIC BACTERIA
	3PC-022	PH STABILITY OF TETRACAINE SOLUTIONS FOR SURFACE ANAESTHESIA
	3PC-023	Investigation of Leachable Compounds In water for injection used in hospital pharmacy
	3PC-024	IMPACT OF PH MODIFICATION ON THE AGGREGATION OF NIVOLUMAB (OPDIVO) IN CLINICAL SOLUTIONS AT 1 AND 5 MG/ML MEASURED BY DYNAMIC LIGHT SCATTERING (DLS) AND SIZEEXCLUSION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-DIODE ARRAY DETECTION (SE/HPLC-DAD)
	3PC-026	Rainer Trittler, Brigitte Altmann, Manuel Garcia-Käufer, Richard Gminski, Martin J. Hug
	3PC-027	DIGITALIZATION SUPPORT SYSTEM FOR INTRAVENOUS MIXTURES ELABORATION IN A BIOLOGICAL SAFETY CABINET
	3PC-028	PHARMACEUTICAL INTERVENTIONS IN PAEDIATRIC PARENTERAL NUTRITION
	3PC-029	STUDY OF PSMA11-68GA ADSORPTION ON MEDICAL DEVICES USED FOR RADIOSYNTHESIS AND MEDIA FILL TEST
	3PC-030	Different substrates for orodispersible films: You have the choice!
	3PC-031	PHYSICOCHEMICAL STABILITY OF helen.linxweiler@unimedizin-mainz.de DILUTED ‘THIOTEPA RIEMSER’ INFUSION SOLUTIONS IN PREFILLED 5% GLUCOSE INFUSION BAGS
	3PC-032	Optimising Analgosedation in the Intensive Care Unit during the SARS-COV-2 Pandemic
	3PC-033	Y-site Compatibility of Intravenous Nefopam with Medications Commonly Used in Intensive Care Units
	3PC-034	DEVELOPMENT AND VALIDATION OF A METHOD FOR THE DETERMINATION OF VANCOMYCIN EYE DROPS BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRY
	3PC-035	Minimising Waste In Oncology

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-002	COVID-19 HOSPITAL VACCINATION CENTER: PATIENT AND NURSE SATISFACTION
	4CPS-003	OUTPATIENT-REPORTED EXPERIENCE IN HOSPITAL PHARMACY AMBULATORY CARE DURING THE COVID19 PANDEMIC
	4CPS-004	IMPACT OF THE SARS-COV PANDEMIC ON THE TRAINING OF HOSPITAL PHARMACY RESIDENTS
	4CPS-005	Evaluating pharmaceutical logistics automated technologies in the hospital setting: a Health Technology Assessment (HTA) approach
	4CPS-006	EVALUATION STUDY OF THE CHAGE IN ADMINISTRATION TIMING OF FIXED COMBINATION: NETUPITANT AND PALONOSETRON IN ONCOHEMATOLOGIC PATIENTS WITH HIGH DOSES OF CARBOPLATIN
	4CPS-008	The role of the pharmacist in the management of Intravenous fluids & electrolytes in adult patients
	4CPS-011	ASSESSMENT OF KNOWLEDGE, ATTITUDES AND PRACTICES REGARDING ANTIBIOTIC RECONSTITUTION AMONG HEALTHCARE PROFESSIONALS IN 12 SOUTHEASTERN EUROPEAN HOSPITALS: A MULTICENTRE CROSS-SECTIONAL STUDY
	4CPS-013	MERGING THE MEDICATION RECONCILIATION AND THE HOSPITALIZATION REPORT TO FORM THE LIAISON LETTER IN A DEPARTMENT OF OTOLARYNGOLOGY
	4CPS-014	CLINICAL RELEVANCE OF PHARMACISTS' INTERVENTIONS IN THE ACUTE WARD
	4CPS-015	SATISFACTION AND INDIRECT IMPACT OF AN OUTPATIENTS’ TELEPHARMACY PROGRAMME
	4CPS-016	Factors influencing the attitudes and opinions of Czech physicians and citizens toward influenza vaccination in Czech pharmacies
	4CPS-017	THE DECISION-MAKING PROCESS IN HEALTH POLICY IMPACTS CLINICAL PRACTICES: A QUALITATIVE STUDY
	4CPS-018	Perceptions of young people regarding pharmaceutical care provided by pharmacists
	4CPS-019	REACTOGENICITY OF THE BNT162B2 (PFIZERBIONTECH) MRNA VACCINE AGAINST COVID-19 IN TERTIARY HOSPITAL WORKERS
	4CPS-020	COMPARISON OF DEPRESCRIBING STRATEGIES: LESSCHRON CRITERIA VERSUS THE GOOD PALLIATIVEGERIATRIC ALGORITHM IN A NURSING HOME
	4CPS-021	POST-STERNOTOMY MEDIASTINITIS: A MEDICOECONOMIC STUDY COMPARING TWO PREVENTIVE STRATEGIES IN CARDIAC SURGERY
	4CPS-022	To vaccinate or not to vaccinate : Impact of a public health action on vaccine hesitancy
	4CPS-023	INDIVIDUALIZATION OF TREATMENT WITH TOCILIZUMAB IN GRAVES ORBITHOPATHY
	4CPS-024	PHARMACEUTICAL INTERVIEWS DEDICATED TO VACCINATION: WHAT ROLE FOR THE CLINICAL PHARMACIST IN MONITORING THE VACCINATION COVERAGE OF AT-RISK PATIENTS ?
	4CPS-025	Adequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab
	4CPS-026	OPTIMISATION OF DIRECT ORAL ANTICOAGULANT TREATMENTS: ANALYSIS OF PRESCRIPTIONS AND PHARMACEUTICAL INTERVIEWS (PI)
	4CPS-027	DESENSITISATION PROTOCOL FOR LIPOSOMAL AMPHOTHERICIN B: A CASE REPORT
	4CPS-028	EFFECTIVENESS AND SAFETY OF CENOBAMATE: EXPERIENCE IN A THIRD-LEVEL HOSPITAL
	4CPS-029	PEMBROLIZUMAB, NIVOLUMAB AND ATEZOLIZUMAB: INCREMENTAL COST-EFFECTIVENESS RATIO
	4CPS-030	SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA IN AN INTENSIVE CARE UNIT
	4CPS-031	EFFICACY AND SAFETY OF HIGH-DOSE TWICE WEEKLY SEBELIPASE ALFA IN SEVERE-ONSET WOLMAN DISEASE: A CASE REPORT
	4CPS-032	Medication errors in prescribing antithrombotics for patients admitted to the hospital in the weekend. A pilot-study
	4CPS-033	Development and evaluation of an amitriptyline topical form for the treatment of cancer-related neuropathy
	4CPS-034	DEPRESCRIBING ORAL IRON IN ELDERLY PATIENTS: EXPERIENCE FROM A NURSING HOME ASSOCIATED WITH A THIRD LEVEL HOSPITAL
	4CPS-035	PHARMACIST-LED MEDICATION RECONCILIATION AT DISCHARGE SHALL NOT BE SUFFICIENT TO REDUCE UNPLANNED HEALTHCARE UTILIZATION: HEAR THE PATIENT EXPERIENCE!
	4CPS-036	IS OUR PROTOCOL FOR THE USE OF TOCILIZUMAB IN COVID PATIENTS ADEQUATE?
	4CPS-037	The 5P-study: Patient and healthcare Provider Perspectives on Potential Preventability of hospital admission for acute exacerbations of Chronic Obstructive Pulmonary Disease
	4CPS-038	Intrapleural colistin for pleural empyema caused by extensively drug-resistant Pseudomonas aeruginosa: A case report
	4CPS-039	EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE TREATMENT OF MIGRAINE
	4CPS-040	INTERINDIVIDUAL VARIABILITY OF LINEZOLID IN CRITICALLY ILL PATIENTS
	4CPS-041	SACUBITRIL/ VALSARTAN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE
	4CPS-042	PHARMACOKINETIC MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS
	4CPS-043	EFFECTIVENESS, SAFETY AND ADHERENCE OF GUSELKUMAB IN MODERATE TO SEVERE PSORIASIS
	4CPS-044	PATIENTS’ PERCEPTIONS OF HEALTHCARE ASSOCIATED-INFECTIONS AND USE OF ANTIBIOTICS IN SURGICAL CONTEXT
	4CPS-045	HEALTHCARE EVALUATION OF HOSPITAL PHARMACY SERVICES BY PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A MULTICENTRE STUDY
	4CPS-046	CARDIOVASCULAR RISK OF HIV PATIENTS
	4CPS-048	IMPROVING SAFETY IN THE USE OF MONOCLONAL ANTIBODIES IN PATIENTS WITH MIGRAINE: AN INTERDISCIPLINARY STUDY
	4CPS-049	MANAGEMENT OF PAN-RESISTANT STENOTROPHOMONAS MALTOPHILIA
	4CPS-050	USE OF GALCANEZUMAB IN PATIENTS WITH MIGRAINE IN A TERTIARY HOSPITAL: HEALTH RESULTS
	4CPS-051	PHARMACOKINETICS ALTERATIONS IN TWO CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL
	4CPS-053	GALCANEZUMAB IN PROPHYLAXIS OF REFRACTORY HIGH-FREQUENCY EPISODIC MIGRAINE IN CLINICAL PRACTICE
	4CPS-054	ANALYSIS OF REAL-WORLD DATA FOR ERENUMAB UTILISATION AND PATIENT-RELATED OUTCOMES
	4CPS-055	SUCCESSFUL SOFOSBUVIR/VELPATASVIR TREATMENT IN A HEPATITIS C PATIENT RECEIVING CHRONIC ANTIEPILEPTIC THERAPY: A CASE REPORT
	4CPS-056	POLYPHARMACY AND POTENTIALLY INAPPROPIATE MEDICATIONS IN OLDER PEOPLE LIVING WITH HIV
	4CPS-057	DISCONTINUATION OF PROTON PUMP INHIBITORS DURING HOSPITALISATION: A RANDOMISED CONTROLLED TRIAL
	4CPS-058	REAL-WORLD EXPERIENCE WITH PROLONGED TEDIZOLID TREATMENT: EFFECTIVENESS AND SAFETY
	4CPS-059	CASE REPORT OF SEVERE HYPERBILIRRUBINEMIA IN A PATIENT CARRYING POLYMORPHISMS IN CES1P1, CDA, SLC22A7 AND ENOSF1 TREATED WITH FLUOROPYRIMIDINES
	4CPS-060	INFLUENCE OF GENETIC POLYMORPHISMS ON THE RESPONSE AND TOXICITY OF CAPECITABINE THERAPY IN PATIENTS WITH BREAST CANCER
	4CPS-061	IMPACT OF PHARMACOGENETICS ON THE TOXICITY OF HIGH-DOSE METHOTREXATE IN A PAEDIATRIC POPULATION
	4CPS-062	RITUXIMAB PHARMACOKINETICS CHARACTERIZATION IN PLASMA AND URINE IN A PATIENT WITH NEPHOTIC SYNDROME
	4CPS-063	ERENUMAB VERSUS GALCANEZUMAB, EFFECTIVENESS IN REAL-LIFE EXPERIENCE
	4CPS-064	QUALITY OF LIFE STUDY: GALCANEZUMAB IN THE TREATMENT OF MIGRAINE
	4CPS-065	SAFETY OF BEVACIZUMAB BIOSIMILAR IN CLINICAL PRACTICE IN NEW AND SWITCHED TREATMENTS
	4CPS-067	PHARMACIST INTERVENTIONS IN SEQUENTIAL ANTIMICROBIAL THERAPY INSIDE AN ANTIMICROBIAL STEWARDSHIP PROGRAMME (ASP)
	4CPS-068	IMPACT OF PHARMACOGENETICS IN SEVERE ALLERGIC ASTHMA PATIENTS TREATED WITH OMALIZUMAB
	4CPS-069	INFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER
	4CPS-070	STUDY OF CARDIOVASCULAR TOXICITY ASSOCIATED WITH IBRUTINIB TREATMENT
	4CPS-071	CYP27B1 GENETIC VARIANTS’ INFLUENCE IN NEPHROTOXICITY DUE TO PLATINUMBASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER
	4CPS-072	BEZLOTOXUMAB FOR THE PREVENTION OF CLOSTRIDIOIDES DIFFICILE RECURRENCE: STUDY IN THE REAL WORLD
	4CPS-073	DESENSITISATION TO IBRUTINIB IN A PATIENT WITH SERIOUS LATE REACTION: A CASE REPORT
	4CPS-075	EVALUATION OF THE COST OF MANAGING ADVERSE EVENTS RELATED TO CYTOTOXIC DRUGS IN CHILDREN
	4CPS-077	GENETICVARIANTSAFFECTINGBISOPROLOL RESPONSEINCARDIOVASCULARDISEASES
	4CPS-078	MOTIVATIONAL INTERVIEWING IN CLINICAL PHARMACIST INTERVENTIONS: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
	4CPS-079	ANALYSIS OF CURRENT RESEARCH IN WEAREABLES : TOWARD A MORE DIGITAL HEALTH
	4CPS-080	EFFICACY AND SAFETY OF THE CONTINUOUS INFUSION OF VANCOMYCIN IN PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW
	4CPS-081	SUBCUTANEOUS FUROSEMIDE INFUSION USING ELASTOMERIC INFUSION PUMPS IN A TERTIARY HOSPITAL
	4CPS-082	ENVIRONMENTAL POLLUTION WITH QUINOLONES IN SPAIN
	4CPS-083	Cost-effectiveness analysis of adalimumab and its clinical alternatives in immunemediated inflammatory diseases in Spain
	4CPS-085	STABILITY OF MEROPENEM AND PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION FOR HOME ADMINISTRATION
	4CPS-086	Inhaled sedation with halogenated agents in the Intensive Care Unit: A literature mini-review
	4CPS-087	THE USE OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR CANCER IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW
	4CPS-088	INDIRECT COMPARISON OF NIVOLUMAB, PEMBROLIZUMAB AND CAMRELIZUMAB IN PATIENTS WITH UNRESECTABLE AND/OR ADVANCED SQUAMOUS CELL CARCINOMA OF ESOPHAGUS IN SECOND-LINE SETTING
	4CPS-089	RISANKIZUMAB IN REFRACTORY HIDRADENITIS SUPPURATIVA TO ANTI-TNFa A CASE REPORT
	4CPS-090	EFFICACY AND SAFETY OF PANGENOTYPS TREATMENTS IN HCV PATIENTS
	4CPS-091	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO HIGH-RISK-DRUGS IN THE EMERGENCY DEPARTMENT
	4CPS-092	BIOLOGICAL THERAPIES FOR THE TREATMENT OF PSORIASIS: EFFECTIVENESS, SAFETY AND ECONOMIC IMPACT OF OPTIMISATION STRATEGIES
	4CPS-093	DRUG-INDUCED SOMNOLENCE IN FRAILTY PATIENTS ATTENDED IN AN EMERGENCY DEPARTMENT
	4CPS-095	APPROPRIATENESS OF EMPIRICAL ANTIBIOTIC THERAPY FOR CERVICITIS AND URETHRITIS PRESCRIBED AT THE EMERGENCY DEPARTMENT
	4CPS-099	CLINICALLY RELEVANT DRUG-DRUG INTERACTION EVENTS IN PATIENTS WITH ABIRATERONE, ENZALUTAMIDE OR APALUTAMIDE TREATMENT
	4CPS-100	INTRADIALYTIC PARENTERAL NUTRITION EFFECTS ON ALBUMIN LEVELS IN MALNOURISHED HAEMODIALYSIS PATIENTS
	4CPS-101	BIOLOGIC AGENTS IN RHEUMATOLOGICAL DISEASES: IMPACT OF ‘TREAT TO TARGET’ IN CLINICAL PRACTICE
	4CPS-102	Drug-related hospital admissions in older adults: comparison of the Naranjo algorithm and an adjusted version of the Kramer algorithm
	4CPS-103	IMPROVING MEDICATION RECONCILIATION REPORTS: EVALUATION THROUGH QUALITY AUDITS
	4CPS-104	PERSISTENCE WITH DISEASE-MODIFYING THERAPY IN MULTIPLE SCLEROSIS PATIENTS
	4CPS-105	CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH HIV INFECTION WITH ANTIRETROVIRAL TREATMENT
	4CPS-106	SAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
	4CPS-107	IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA: EFFECTIVENESS AND SAFETY IN CLINICAL PRACTICE
	4CPS-108	BIOMARKERS EVOLUTION IN PATIENTS WITH SARSCOV-2 PNEUMONIA TREATED WITH BARICITINIB
	4CPS-109	DESCRIPTIVE ANALYSIS OF PATIENTS CO-INFECTED WITH HIV AND HEPATITIS C VIRUS (HCV) TREATED WITH ANTIVIRALS FOR HCV AND ITS EFFICACY IN A PRISON FROM 2002 TO 2020
	4CPS-110	INITIAL EXPERIENCE OF THE USE OF CEFIDEROCOL FOR MULTIDRUG RESISTANT INFECTIONS IN A UNIVERSITY HOSPITAL
	4CPS-111	RUXOLITINIB FOR REFRACTORY GRAFT-VERSUS-HOST DISEASE IN PAEDIATRIC PATIENTS
	4CPS-112	VORICONAZOLE THERAPEUTIC DRUG MONITORING: RELATIONSHIP WITH LIVER TOXICITY
	4CPS-113	REAL-LIFE DATA ON THE USE OF ABIRATERONE/ ENZALUTAMIDE IN CASTRATION-RESISTANT PROSTATE CANCER
	4CPS-114	INTEGRATION OF A PHARMACIST INTO A GERIATRIC DEPARTMENT
	4CPS-115	NABPACLITAXEL PLUS GEMCITABINE VERSUS FOLFIRINOX IN METASTATIC PANCREATIC CANCER: REAL WORLD DATA EXPERIENCE
	4CPS-116	ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE
	4CPS-117	APPROPRIATENESS OF ANTIBIOTIC PRESCRIPTIONS IN A LONG-TERM CARE FACILITY
	4CPS-119	REAL-WORLD EXPERIENCE WITH PCSK9 INHIBITORS PROTOCOL FOR HYPERCHOLESTEROLEMIA
	4CPS-120	ADVERSE DRUG REACTION (ADR) NOTICATIONS’ IMPACT ON PATIENTS FOLLOWED AT AN AMBULATORY CARE PHARMACY UNIT
	4CPS-121	CLINICAL PHARMACIST INTERVENTIONS IN THE EMERGENCY DEPARTMENT AND THEIR IMPACT ON PREVENTABLE ADVERSE DRUG EVENTS
	4CPS-122	OVERVIEW OF THE IMPACT OF PENICILLIN ALLERGY LABELS ON ANTIBIOTIC USE IN THE EMERGENCY DEPARTMENT
	4CPS-123	PERFORMANCE OF MOST COMMONLY USED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN CRITICALLY ILL PATIENTS
	4CPS-124	COST OPTIMISATION PLAN IN IMMUNOTHERAPY
	4CPS-125	SINGLE-AGENT BEVACIZUMAB IN OFF-LABEL TREATMENT OF RECURRENT OR REFRACTORY GLIOMA
	4CPS-126	REAL-WORLD PERSISTENCE WITH FAMPRIDINE AMONG MULTIPLE SCLEROSIS PATIENTS
	4CPS-127	THERAPEUTIC DRUG MONITORING WITH BIOLOGICAL DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
	4CPS-129	ADJUST DOSES OF ANTIBIOTICS IN PATIENTS WITH RENAL INSUFFICIENCY
	4CPS-130	Analysis of the Different Cardioversion Strategies in the Emergency Department in a Secondary Hospital
	4CPS-131	SWITCHING AND DISCONTINUATION OF DISEASE-MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS: EXPERIENCE IN AN UNIVERSITY HOSPITAL
	4CPS-133	ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT
	4CPS-134	OPTIMIZATION OF DENOSUMAB PRESCRIPTION IN OSTEOPOROSIS PATIENTS
	4CPS-136	PERSISTENCE OF FIRST-LINE BIOLOGICAL THERAPY IN PATIENTS WITH CROHN’S DISEASE
	4CPS-137	Prospective analysis of clinical pharmacist interventions for QT drug-drug interactions alongside clinical decision support
	4CPS-138	THERAPEUTIC DRUG MONITORING OF INTRAVENOUSBUSULFANINPAEDIATRICPATIENTS
	4CPS-140	ANTIMICROBIAL STEWARDSHIP PROGRAM IN ONCOLOGY PATIENTS THROUGH A MULTIDISCIPLINARY TEAM
	4CPS-141	ASSESSMENT OF TEDIZOLID FOR USE IN GRAM-POSITIVE BACTERIAL INFECTIONS BACKGROUND: REAL WORLD DATA
	4CPS-142	EFFECTIVENESS AND SAFETY OF ATEZOLIZUMAB IN METASTATIC UROTHELIAL CARCINOMA
	4CPS-145	EFFECTIVENESS AND SAFETY OF BARICITINIB AND TOFACITINIB IN REUMATOID ARTHRITIS IN CLINICAL PRACTICE
	4CPS-146	Development and validation of a rapid High Performance Liquid Cromatography method (HPLC) for the determination of triazoles in human plasma
	4CPS-147	EXPERIENCE OF USE OF BIOLOGICAL ANTIMIGRAINE TREATMENTS IN CLINICAL PRACTICE
	4CPS-148	Use of remdesivir in severe Sars-CoV-2 pneumonia in critically and non-critically ill patients
	4CPS-149	HOSPITAL AT HOME COVID UNIT: MULTIDISCIPLINARY STRATEGIES
	4CPS-150	Ability to assess acute kidney injury in patients admitted to hospital
	4CPS-152	CHARACTERIZATION OF A COMPOUNDED VORICONAZOLE SOLUTION FOR NEBULIZATION AND DESCRIPTION OF ITS USE IN THE CLINICAL SETTING
	4CPS-154	STEVENS–JOHNSON SYNDROME IN A PREGNANT WOMAN CAUSED BY PYRIMETHAMINE AND SULFADIZINE
	4CPS-155	APPROPRIATENESS OF PHARMACOTHERAPY IN NURSING HOMES: PHARMACY AND GERIATRICS SERVICES COORDINATION PROJECT
	4CPS-156	ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A GENERAL SURGERY SERVICE: ROLE OF THE PHARMACIST
	4CPS-157	IMPACT OF COVID-19 PANDEMIC ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AND ENZYME REPLACEMENT THERAPIES
	4CPS-161	BUDGETARY IMPACT OF PCSK9I DOSES REGIMEN OPTIMISATION
	4CPS-162	CYTOKINE RELEASE SYNDROME IN ONCOHAEMATOLOGICAL PATIENTS TREATED WITH TOCILIZUMAB
	4CPS-163	EARLY EXPERIENCES IN SWITCHING BETWEEN MONOCLONAL ANTIBODIES IN CHRONIC MIGRAINE PREVENTIVE THERAPY
	4CPS-164	DURABILITY OF ORAL DUAL ANTIRETROVIRAL THERAPY IN HIV PATIENTS
	4CPS-165	HAS COVID AFFECTED THE TREATMENT OF ONCOLOGY PATIENTS?: A DESCRIPTIVE STUDY OF TREATMENTS FROM 2019 TO 2021
	4CPS-166	ASSOCIATION BETWEEN IMMUNE-RELATED EFFECTS AND EFFECTIVENESS OF FIRST-LINE PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER
	4CPS-167	SODIUM AND MAGNESIUM ALTERATIONS IN THE CRITICAL PATIENT WITH SARS-CoV-2 AND PARENTERAL NUTRITION
	4CPS-170	Review of new biomarkers that predict the pharmacokinetics of biologic drugs in inflammatory bowel disease
	4CPS-171	EFFECT OF LIPIDIC COMPOSITION OF PARENTERAL NUTRITION ON THE DEVELOPMENT OF HYPERTRIGLYCERIDAEMIA AND CHOLESTASIS
	4CPS-172	POSACONAZOL THERAPEUTIC DRUG MONITORING IN A PAEDIATRIC TERTIARY HOSPITAL
	4CPS-173	PHARMACEUTICAL INTERVENTION IN BROAD-SPECTRUM ANTIBIOTIC PRESCRIPTION IN HOSPITALIZED PATIENTS
	4CPS-174	EFFECTIVENESS OF OBETICOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS E
	4CPS-175	MEDICATION REGIMEN COMPLEXITY INDEX AMONG SOLID ORGAN TRANSPLANT PATIENTS
	4CPS-176	ORAL IVERMECTIN EFFECTIVENESS IN THE TREATMENT OF PERMETHRIN-RESISTANT SCABIES: A DESCRIPTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY
	4CPS-177	A QUALITATIVE STUDY ON PHARMACIST PRESCRIBING FOR PATIENTS WITH CHRONIC KIDNEY DISEASE
	4CPS-178	THERAPEUTIC DRUG MONITORINGOF GENTAMICIN AFTER PRE-DIALYSIS ADMINISTRATION
	4CPS-179	“Description and Follow-up of the Use of Emtricitabin/ Tenofovir for HIV Pre-Exposure Prophylaxis
	4CPS-182	INCREASE IN THE PRESCRIPTION OF BENZODIAZEPINES IN THE CONTEXT OF THE SARSCOV-2 PANDEMIC
	4CPS-183	Prevention of coronavirus contamination from the environment using an air-cleaning closed system drug-transfer device
	4CPS-185	A toll for Hospital Pharmacist Interventions optimization
	4CPS-186	2020 ANTIMICROBIAL CONSUMPTION INDICATORS: ANALYSIS COMPARED WITH PREVIOUS YEARS
	4CPS-187	Pharmacist-clinician Collaborative Study for Prospective Identification of Drug Interactions on HIV Patients
	ACPS-189	ASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPILIMUMAB IN ADVANCED MELANOMA
	4CPS-190	TELEPHARMACY: A PILOT EXPERIENCE IN TIMES OF COVID-19 IN A TERTIARY HOSPITAL
	4CPS-191	SWITCH TO BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA
	4CPS-192	IMPACT OF THE SARS-COV-2 PANDEMIC ON THE USE OF ANTIFUNGALS IN AN INTENSIVE CARE UNIT IN A THIRD-LEVEL HOSPITAL
	4CPS-193	Selection of clinical rules for the screening of high-risk situations in paediatric medicine
	4CPS-194	CLINICAL IMPACT OF A PHARMACIST-LED DISCHARGE MEDICATION REVIEW SERVICE: AN ANALYSIS OF PREVALENCE AND ACCEPTANCE OF INTERVENTIONS
	4CPS-195	Medication-related readmissions: documentation and communication to the next healthcare providers and patients
	4CPS-197	Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs
	4CPS-198	THE IMPACT OF A PHARMACIST-LED MEDICATION REVIEW ON THE MEDICINE RISK SCORE: A NONRANDOMISED CONTROLLED STUDY
	4CPS-199	EVALUATION OF FREMANEZUMAB RESPONSE IN MIGRAINE PROPHYLAXIS
	4CPS-200	EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE PREVENTION OF MIGRAINE
	4CPS-201	Audit on the prescription and administration of Parkinson’s Disease medication on admission to hospital
	4CPS-202	OPTIMISATION OF SUBCUTANEOUS BIOLOGICAL THERAPIES IN RHEUMATIC AND DERMATOLOGICAL DISEASES
	4CPS-203	COMPARISON OF PIRFENIDONE VERSUS NINTENDANIB IN IDIOPATHIC PULMONARY FIBROSIS
	4CPS-204	AN EXPLORATION OF PATIENTS’ PERCEPTIONS OF COLORECTAL CANCER AND ITS MANAGEMENT: A QUALITATIVE STUDY AT INITIATION OF TREATMENT WITH CHEMOTHERAPY
	4CPS-206	RIBOCICLIB AS FIRST LINE FOR METASTASIC BREAST CANCER: ANALISIS OF USE AND SECURITY
	4CPS-207	IMPROVING THE SAFETY OF PHARMACOTHERAPY IN PAEDIATRIC HAEMATO-ONCOLOGY BY CLINICAL PHARMACY SERVICES
	4CPS-209	Benefit of Medication Reviews by a Renal Pharmacist in the Setting of a Computerized Physician Order Entry System
	4CPS-210	IMPACT OF THE ANTIBIOTIC THERAPY USED DURING THE SARS-COV-2 PANDEMIC ON THE INCIDENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION
	4CPS-211	Reduction of flushing volume and incompatibilities by a clinical pharmacist in a paediatric intensive care unit
	4CPS-212	INSTRUCTIONS GIVEN BY THE ANAESTHETIST ON THE MANAGEMENT OF CHRONIC TREATMENTS PREOPERATIVELY: WHAT DOES THE PATIENT REALLY UNDERSTAND AND RETAIN? AN OBSERVATIONAL STUDY
	4CPS-213	A COMPARATIVE RISK ANALYSIS COMPARING THE CONVENTIONAL AND FULLY AUTOMATED MANAGEMENT OF CLINICAL TRIALS IN AN ONCOLOGY PHARMACY
	4CPS-214	EXPERIENCE OF USE OF CANNABIDIOL IN PAEDIATRIC PATIENTS
	4CPS-215	PERSISTENCE AND THERAPEUTIC ADHERENCE TO FIRST GENERATION JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS
	4CPS-217	CLINICAL, ECONOMIC AND ORGANISATIONAL IMPACT OF PHARMACISTS’ INTERVENTIONS IN ONCOLOGICAL CARE PATIENTS
	4CPS-218	EVALUATION OF THE IMPACT OF INCORPORATING A PHARMACIST INTO A HOSPITAL EMERGENCY DEPARTMENT
	4CPS-221	POTENTIALLY INAPPROPRIATE MEDICINES IN OLDER PATIENTS
	4CPS-222	ADHERENCE IN POLYMEDICATED ELDERLY PATIENTS ADMITTED TO A TRAUMA WARD
	4CPS-223	ADHERENCE TO ABIRATERONE AND CORTICOID IN PATIENTS WITH PROSTATE CANCER
	4CPS-224	IMPACT OF PROACTIVE MEDICATION RECONCILIATION PRIOR TO PRE-ANAESTHESIC CONSULTATION
	4CPS-225	Integration of a clinical pharmacist in a therapeutic education team for diabetic patients: an initiative that is worth gold!
	4CPS-226	THE ROLE OF THE CLINICAL PHARMACIST IN THE SCREENING OF CANDIDATES FOR ONCOHAEMATOLOGICAL CLINICAL TRIALS
	4CPS-227	Feedback from a French region on the use of e - Therapeutic Patient Education during the health crisis: high-speed interviews!
	4CPS-229	Implementation of an interprofessional pre-operative medication management program in cardiac surgery – a pre post quality improvement study
	4CPS-231	ARE WE SUSTAINABLE? A BASELINE QUESTIONNAIRE REGARDING THE ENVIRONMENTAL IMPACT OF PHARMACY PRACTICE ACROSS THE COUNTRY
	4CPS-232	Pharmacist-led medication review unveiled more medication-related problems in possibly medication-related hospitalisations than in unlikely medication-related hospitalisations in elderly patients
	4CPS-233	THERAPEUTIC SWITCH OF ANTIRETROVIRAL TREATMENTS: EFFICACY, TOLERABILITY AND REASON FOR CHANGE
	4CPS-234	IMPACT OF AN INTENSIVE MONITORING PROGRAM ON METHOTREXATE ELIMINATION
	4CPS-235	PROFILE OF USE OF PHARMACOTHERAPY IN PSORIASIS, BIOLOGICAL DRUGS AND BIOSIMILARS
	4CPS-237	MEASURING ADHERENCE TO ANTIRETROVIRAL TREATMENT: CORRELATION AND CONCORDANCE BETWEEN TWO INDIRECT METHODS
	4CPS-239	IMPACT OF KNOWLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION ON THE QUALIY OF LIFE OF PEOPLE LIVING WITH HIV
	4CPS-240	DEVELOPMENT OF A 25% BENZYL BENZOATE LOTION FOR A CASE OF RESISTANT NORWEGIAN SCABIES
	4CPS-241	Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Tenofovir alafenamide, Emtricitabine and Bictegravir in a Real-Life Cohort of HIV-Infected Adults
	4CPS-242	HUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS: ANALYSIS, FOLLOW-UP AND PANDEMIC EFFECT
	4CPS-243	INFLUENCE OF VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION ON THE PHARMACOKINETICS OF VANCOMYCIN IN ADULTS: CAN AN OPTIMAL PHARMACODYNAMIC TARGET BE ACHIEVED?
	4CPS-244	CARDIOVASCULAR, RENAL AND BONE EVALUATION OF A HIV POPULATION OVER 60 YEARS OLD
	4CPS-245	INAPPROPRIATE ANTIBIOTIC DOSAGE ADJUSTMENTS IN PATIENTS WITH RENAL IMPAIRMENT: A CROSS-SECTIONAL ANALYSIS
	4CPS-246	MEDICATION-RELATED ADMISSION WAS MORE FREQUENT IN ELDERLY PATIENTS HOSPITALISED IN AN ORTHOPEDIC UNIT THAN IN AN EMERGENCY DEPARTMENT IN TWO FRENCH HOSPITALS
	4CPS-247	EVALUATION OF THE CLINICAL IMPACT OF MEDICATION RECONCILIATION ON ADMISSION USING THE CLEO TOOL
	4CPS-249	ELTROMBOPAG FOR TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA ASSOCIATED WITH COVID-19 VACCINE: A CASE REPORT
	4CPS-250	HOME DELIVERY FOR OUTPATIENTS WITH IMMUNEMEDIATED DISEASES: EXPERIENCE AND PATIENT SATISFACTION
	4CPS-251	INFLUENCE OF POLYPHARMACY AND COMORBIDITIES IN THE QUALITY OF LIFE OF PATIENTS WHO SUFFER HIP FRACTURE
	4CPS-252	ORAL AND INTRAVENOUS IRON IN THE TREATMENT OF PERIOPERATIVE ANAEMIA
	4CPS-253	DIFFERENCES BETWEEN PHARMACEUTICAL INTERVENTIONS PERFORMED ON ANTIMICROBIALS IN MEDICAL AND SURGICAL SERVICES
	4CPS-257	EFFECTIVENESS AND SAFETY OF NINTEDANIB AND PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
	4CPS-258	ACTIVATION, ADHERENCE AND HEALTH OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH BIOLOGICAL DRUGS
	4CPS-259	ANALYSIS OF THE ANTICHOLINERGIC LOAD IN POLYMEDICATED ELDERLY PATIENTS WHO HAVE SUFFERED A FALL
	4CPS-260	PERSISTENCE AND SAFETY OF CALCITONIN GENERELATED PEPTIDE INHIBITORS IN CHRONIC MIGRAINE
	4CPS-262	EVALUATION OF DRY EYE SEVERITY AND THERAPEUTIC ADHERENCE OF PATIENTS ON AUTOLOGOUS SERUM EYE DROPS
	4CPS-263	EVALUATION OF THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS TOCILIZUMAB
	4CPS-264	ANALYSIS OF MEDICAL TREATMENT, RISK FACTORS AND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE NOSOCOMIAL DIARRHOEA
	4CPS-265	CHRONIC COMPLEX PALLIATIVE PAEDIATRIC PATIENT AT-HOME CARE UNIT: PHARMACOTHERAPEUTIC PROFILE AND ANALYSIS OF SIALORRHEA TREATMENT
	4CPS-266	Detection and follow-up of drug related problems for patients with cardiovascular disease: A study of the Medicine Start Service in hospital pharmacies
	4CPS-267	Design, implementation, and evaluation of a medication counselling service provided by pharmacists using teach-back at hospital discharge
	4CPS-269	ANALYSIS OF RECURRENCES AND RISK FACTORS IN INFECTION BY CLOSTRIDIUM DIFFICILE
	4CPS-270	Investigating the Use of Patient Frailty to Guide Pharmacist-led Medication Review
	4CPS-271	ADHERENCE TO MEPOLIZUMAB AND BENRALIZUMAB IN REAL CLINICAL PRACTICE
	4CPS-272	INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY DYSPHAGIA SCREENING TEAM IN AN INTERMEDIATE AND LONG STAY HOSPITAL
	4CPS-273	IMPACT OF A SPECIALIST PHARMACIST ON HEPATOPANCREATICO-BILIARY (HPB) SURGICAL WARD ROUNDS AT A LARGE TERTIARY LIVER CENTRE
	4CPS-274	Evaluation of pharmaceutical interventions documented by a pharmacy technician: Where do pharmacy technicians have the biggest impact to avoid drug-related problems?

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-002	ADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS
	5PSQ-003	DEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY
	5PSQ-004	ANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS
	5PSQ-006	DOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY
	5PSQ-008	ASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL
	5PSQ-009	Patient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study
	5PSQ-010	Identification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety
	5PSQ-011	INTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE
	5PSQ-012	ARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION?
	5PSQ-013	ANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS
	5PSQ-014	SAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB
	5PSQ-015	ANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES
	5PSQ-016	ACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE?
	5PSQ-017	MAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY
	5PSQ-018	ANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA
	5PSQ-019	ASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-2
	5PSQ-021	Patient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden
	5PSQ-022	DESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT
	5PSQ-023	Neutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer
	5PSQ-024	Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC)
	5PSQ-025	ANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV
	5PSQ-026	CLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS
	5PSQ-027	Misuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units
	5PSQ-028	ASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT
	5PSQ-029	EVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE
	5PSQ-030	USE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS
	5PSQ-031	EVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM
	5PSQ-032	COMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING
	5PSQ-033	Positive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany
	5PSQ-034	HOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS
	5PSQ-035	INTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD”
	5PSQ-036	IMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY
	5PSQ-038	DEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE
	5PSQ-040	PHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW
	5PSQ-041	SAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW
	5PSQ-042	TOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS
	5PSQ-043	BENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL
	5PSQ-044	CONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT
	5PSQ-045	ANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL
	5PSQ-046	IMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL
	5PSQ-048	ANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY
	5PSQ-049	STARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT
	5PSQ-051	COST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION
	5PSQ-053	INFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY
	5PSQ-054	ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION
	5PSQ-055	LONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT
	5PSQ-056	LOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY
	5PSQ-057	ACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING
	5PSQ-058	EFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS
	5PSQ-059	CHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL
	5PSQ-060	LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE
	5PSQ-062	REAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS
	5PSQ-063	PERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA
	5PSQ-065	INMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS
	5PSQ-066	PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME
	5PSQ-067	ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE
	5PSQ-068	INCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA
	5PSQ-069	DOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS?
	5PSQ-070	USEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION
	5PSQ-071	REAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS
	5PSQ-074	COVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE
	5PSQ-076	EVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION
	5PSQ-077	BEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY
	5PSQ-078	THROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA
	5PSQ-080	ERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING
	5PSQ-081	IMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME
	5PSQ-082	EFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS
	5PSQ-083	USE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT
	5PSQ-084	HOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS
	5PSQ-085	REAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER
	5PSQ-086	EVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION
	5PSQ-087	LONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES
	5PSQ-088	ANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE
	5PSQ-090	USE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE
	5PSQ-091	DALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS
	5PSQ-092	TREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB
	5PSQ-093	PERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS
	5PSQ-094	REASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS
	5PSQ-095	COMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE
	5PSQ-097	USE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS
	5PSQ-098	EXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
	5PSQ-101	MEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL
	5PSQ-103	DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS
	5PSQ-104	VOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC
	5PSQ-105	INSULIN PERFUSION IN NEONATOLOGY. WHICH ONE IS THE SAFEST?
	5PSQ-106	IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) RECONSTITUTION IN A UNIVERSITY TEACHING HOSPITAL IN FRANCE : PROPOSAL OF A DECISION-MAKING ALGORITHM
	5PSQ-107	SECURIZING OF TISAGENLECLEUCEL THAWING AND DELIVERING
	5PSQ-108	SECURIZING OF TISAGENLECLEUCEL (KYMRIAH®) STORAGE
	5PSQ-110	OMEPRAZOLE DEPRESCRIPTION PROJECT IN A SOCIAL HEALTH CENTER WITH A DEPOSIT OF MEDICINES ASSOCIATED WITH A HOSPITAL PHARMACY SERVICE
	5PSQ-111	PHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS
	5PSQ-112	HIDDEN HARM? ASSESSING MAGNITUDE AND COSTS OF INTRAVENOUS THERAPY ADMINISTRATION ERRORS VIA SMART PUMP REPORTS
	5PSQ-115	ANALYSIS OF MEDICATION ERRORS INVOLVING HIGH-RISK PATIENTS IN THE PERIOPERATIVE SETTING
	5PSQ-116	Medication-related follow-up of older patients after hospital discharge: a multicentre retrospective chart review
	5PSQ-117	DETERMINATION OF GENETIC POLYMORPHISMS IN THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN A PATIENT WITH GASTRIC ADENOCARCINOMA TREATED WITH FLUOROPYRIMIDINES: A CASE REPORT
	5PSQ-118	LITHIUM THERAPY ON HOSPITAL ADMISSION
	5PSQ-120	IMPACT OF THE COVID-19 PANDEMIC ON THE USE OF ANTIMICROBIALS IN PRIMARY AND HOSPITAL CARE
	5PSQ-121	IMPORTANCE OF CONCILIATION IN IMMUNOSUPPRESSANT TREATMENT
	5PSQ-122	EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION
	5PSQ-123	ORPHAN OFF-LABEL DRUG: IS IT REALLY COMMON PRACTICE?
	5PSQ-124	THE ROLE OF THE CLINICAL PHARMACIST AVOIDING MEDICATION ERRORS IN A CLINICAL RESEARCH ONCO-HEMATOLOGIC UNIT
	5PSQ-125	THE IDENTIFICATION OF HEALTH CONSEQUENCES ASSOCIATED WITH COUNTERFEIT MEDICINE AND ILLEGAL HEALTH PRODUCT APPLICATION USING PHARMACOVIGILANCE DATA
	5PSQ-128	CLINICAL INTERVENTIONS IN THE AREA OF INPATIENT PRESCRIPTIONS PERFORMED BY HOSPITAL PHARMACY RESIDENT
	5PSQ-130	DOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME
	5PSQ-131	PARENTERAL NUTRITION IN ACUTE PANCREATITIS: A REVIEW OF APPROPRIATENESS
	5PSQ-132	ANALYSIS OF CHEMICAL CONTAMINATION BY HAZARDOUS DRUGS WITH SEMIQUANTITATIVE SYSTEM IN A TERTIARY HOSPITAL
	5PSQ-133	ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER
	5PSQ-134	PATIENTS’ SATISFACTION TOWARD PHARMACEUTICAL CARE AT A UNIVERSITY HOSPITAL
	5PSQ-135	NEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK
	5PSQ-137	MEDICATION ERRORS RELATING TO ISOAPPEARANCES IN THE EMERGENCY ROOM
	5PSQ-138	IMPACT OF HIGH TEMPERATURE, SHAKING AND LIGHT ON QUALITY OF THE THERAPEUTIC PEPTIDE TEDUGLUTIDE (REVESTIVE®) EVALUATED BY LC/MS/MS (ORBITRAP) PEPTIDE MAPPING ANALYSIS AND STRESS
	5PSQ-139	ANTICHOLINERGIC RISK EVALUATION IN HOSPITALISED PATIENTS
	5PSQ-140	PATIENT SAFETY CLIMATE IN A HOSPITAL PHARMACY DEPARTMENT
	5PSQ-141	Personalized therapy for interstitial lung diseases in caused by ABCA3 mutations
	5PSQ-144	Development and validation of clinical rules to address risk prescriptions
	5PSQ-145	MEDICINAL PLANTS USE AMONG TUNISIAN PATIENTS: PREVALENCE AND PERCEPTION
	5PSQ-146	RISK MAPPING OF DRUG MANAGEMENT IN A PRISON
	5PSQ-147	A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO THE MEDICAL DEVICES MANAGEMENT PROCESS IN A HOSPITAL PHARMACY
	5PSQ-148	TANDEM PROJECT: TRANSITIONS OF CARE AND MEDICATION RECONCILIATION IN HIGH-RISK PATIENTS
	5PSQ-149	DURVALUMAB FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER: REAL-WORLD EXPERIENCE
	5PSQ-150	Implementation of a Programme for Optimising the Use of Antibiotics (PROA) in the Paediatrics Emergency Care Unit of a third level hospital
	5PSQ-151	OPTIMIZATION OF THE SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB
	5PSQ-152	EFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS
	5PSQ-153	PERSISTENCE AND REASONS FOR DISCONTINUATION OF TREATMENT WITH APREMILAST IN DERMATHOLOGICAL DISEASES
	5PSQ-154	Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Antimicrobial Resistance
	5PSQ-155	HOW IS CHEMOTHERAPY USED AT THE END OF LIFE IN A SECONDARY HOSPITAL?
	5PSQ-156	REASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION
	5PSQ-157	SEVERE NEUROTOXICITY OF ORAL IVERMECTIN: A SYSTEMATIC REVIEW OF CASES AND CASE SERIES
	5PSQ-158	Food and drink management as part of medicaton administration safety

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	CAN PHARMACISTS IMPROVE THEIR PATIENT COMMUNICATION BY READING FICTION?
	6ER-002	Applying reflective Multicriteria Decision Analysis to understand the value of therapeutic alternatives in the management of anaemia in gynaecologic surgery
	6ER-005	REDUCING INVASIVE DEVICE-RELATED BLOODSTREAM INFECTIONS: A CHALLENGE FOR THE PREVENTION OF HEALTH-CARE ASSOCIATED INFECTIONS
	6ER-006	PARACETAMOL VERSUS IBUPROFEN FOR TREATMENT OF PERSISTENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM INFANTS: IBUPAR-TRIAL
	6ER-007	REAL-WORLD EFFECTIVENESS OF GENE THERAPY ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA) FOR SPINAL MUSCULAR ATROPHY: A REVIEW
	6ER-008	DEVELOPMENT OF A RISK-SHARING MODEL BASED ON THE CLINICAL PERFORMANCE OF ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA)
	6ER-011	COTRIMOXAZOL: HOW FOLATE SUPPLEMENTATION COULD AFFECT TREATMENT EFFICACY
	6ER-012	EFFECTIVENESS OF IL-23 INHIBITORS IN PATIENTS WITH MODERATE–SEVERE CHRONIC PLAQUE PSORIASIS
	6ER-013	ANALYSIS OF PATIENTS’ MORTALITY IN SARS-COV-2 INFECTION DURING THE FIRST MONTH OF HOSPITAL ADMISSION
	6ER-014	ANALYSIS OF THE EVOLUTION OF INTERLEUKIN-6 IN COVID-19 PATIENTS AFTER BEING TREATED WITH DEXAMETHASONE
	6ER-015	MUTATIONS IN THE FACTOR VIII GENE IN OUR HAEMOPHILIA A POPULATION
	6ER-017	PREVENTION OF EXTRAVASATION BY THE LOCAL APPLICATION OF HYBRID AEROGEL MICROPARTICLES AS DRUG DELIVERY SYSTEMS FOR CERVICAL CANCER CHEMOTHERAPY
	6ER-018	USE OF ELTROMBOPAG IN ROUTINE CLINICAL PRACTICE
	6ER-019	DETERMINATION OF DOXORUBICIN FROM THE EFLUATE OF CELLS USING THE DRUGLOG® SYSTEM
	6ER-020	The occurrence of fluid overload in critically ill patients: is there a need for fluid stewardship?
	6ER-021	EVALUATION OF COVID MORTALITY DURING HOSPITAL ADMISSION IN PATIENTS RECEIVING ONCOLOGIC TREATMENT
	6ER-022	PHARMACOLOGICAL FACTORS RELATED TO HOSPITAL ADMISSIONS IN POLYMEDICATED ELDERLY PATIENS
	6ER-023	STUDY OF THE USE OF CEFTAZIDIMA-AVIBACTAM IN A THIRDLEVEL UNIVERSITY HOSPITAL
	6ER-024	POTENTIALLY DRUG-RELATED PROBLEMS IN A POLYMEDICATED POPULATION
	6ER-025	Real-life use of remdesivir in hospitalized COVID-19 patients with severe pneumonia: an observational study from an Italian University Hospital
	6ER-026	EFFECTIVENESS AND SAFETY OF APREMILAST IN A THIRD-LEVEL HOSPITAL
	6ER-027	BLOOD CYTOKINE EVALUATION IN PATIENTS WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION
	6ER-027	BLOOD CYTOKINE EVALUATION IN PATIENTS WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION
	6ER-028	MARKET EXCLUSIVITY EXPIRY HAS LIMITED EFFECT ON PRICES OF BRAND-NAME ORPHAN DRUGS
	6ER-029	Game-based training: play instead of reading boring procedures!

25th Anniversary EAHP Congress - Hospital Pharmacy 5.0 - the future of patient care (2021)

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	IMPACT OF AN ORAL NUTRITION PROTOCOL IN PATIENTS TREATED WITH ELECTIVE RADICAL CYSTECTOMY: A LONG TERM FOLLOW-UP (submitted in 2019)
	NP-002	MEDICATION SAFETY IN PATIENTS TREATED WITH ORAL ANTITUMOR AGENTS: A PROSPECTIVE, RANDOMIZED INVESTIGATION TO IMPROVE PATIENT SAFETY AND WELL-BEING BY INTENSIFIED CLINICAL PHARMACEUTICAL/ PHARMACOLOGICAL CARE (submitted in 2019)
	NP-003	STEADY-STATE PHARMACOKINETICS AND EARLY SAFETY DATA IN HIV-INFECTED AFRICAN CHILDREN WEIGHING ≥25KG AFTER SWITCHING TO 50MG FILM-COATED DOLUTEGRAVIR TABLETS IN THE ODYSSEY TRIAL (submitted in 2019)
	NP-004	INITIATION OF A CLINICAL PHARMACIST LED, PROSPECTIVE AUDIT ON ANTIBIOTIC PRESCRIBING (submitted in 2019)
	NP-005	IMPLEMENTING MEDICATION RECONCILIATION ON HOSPITAL ADMISSION: A MULTICENTER PILOT STUDY IN ESTONIA AND FINLAND (submitted in 2019)
	NP-006	A PAIR OF PHARMACY TECHNICIAN / NURSE TO TRAIN ON THE ANTI-RETURN VALVES (submitted in 2019)
	NP-007	A MIXED METHODS EVALUATION OF THE CROSS-SECTOR PHARMACIST VOCATIONAL TRAINING FOUNDATION PROGRAMME: IS THE TRAINING PROGRAMME FIT FOR PURPOSE? (submitted in 2019)
	NP-008	MONITORING OF PRESCRIPTIONS ON PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN BEATRIZ ÂNGELO HOSPITAL (submitted in 2019)
	NP-009	THE IMPACT OF TNFa INHIBITORS ON GLUCOCORTICOIDS USE AMONG PATIENTS WITH ARTHRITIDES (submitted in 2019)
	NP-010	CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE (submitted in 2019)
	NP-011	MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT – PROCESS ASSESSMENT FOR A MORE EFFICIENT SERVICE (submitted in 2019)
	NP-012	COST EFFECTIVENESS ANALYSIS AND INDIRECT COMPARISON CAN SUPPORT THE PRICE’ DEFINITION OF A DRUG? THE CASE OF ENCORAFENIB AND BINIMETINIB IN METASTATIC MELANOMA, THE PHARMACIST’POINT OF VIEW (submitted in 2019)
	NP-013	THE NEOCHECK PROJECT: DEVELOPMENT OF A PRESCRIPTION-SCREENING TOOL SPECIFIC TO NEONATOLOGY (submitted in 2019)
	NP-014	MEDICINE BOXES FOR DISTRIBUTION OF PAID PHARMACEUTICALS TO OUTPATIENTS IN THE FUTURE (submitted in 2019)
	NP-015	QUALITY ASSESSMENT OF 3D PRINTED SILDENAFIL AND FUROSEMIDE TABLETS FOR THE PAEDIATRIC POPULATION USING AN INNOVATIVE EXTRUSIONBASED TECHNIQUE
	NP-016	EPIDEMIOLOGY AND RESISTANCE MAP TO AID ANTIBIOTIC GUIDELINE DEVELOPMENT SINGLE CENTRE RETROSPECTIVE STUDY FROM AN EMERGENCY DEPARTMENT
	NP-017	RISK ASSESSMENT OF OCCUPATIONAL EXPOSURE TO CYTOTOXIC DRUGS IN AN OUTPATIENT HOSPITAL PHARMACY
	NP-018	BUILDING CAPACITY WITHIN A HEPATITIS C TREATMENT MODEL. THE VALIDATION PROCESS FOR A HEPATITIS C PRE-TREATMENT PHARMACIST ASSESSMENT COMPLEX INTERVENTION TOOLKIT
	NP-019	DEVELOPMENT OF A CONVERSION FACTOR BETWEEN DEFINED DAILY DOSES OF ADULTS AND NEONATES
	NP-020	ANTINEOPLASTIC AND OTHER HAZARDOUS DRUGS: RISK POTENTIAL AND EXPOSURE – LESS IS MORE!

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	CAN RIVAROXABAN BECOME COST SAVING COMPARED WITH VITAMIN K ANTAGONISTS IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE? (submitted in 2019)
	1ISG-002	BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS (submitted in 2019)
	1ISG-003	STUDY OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS DURING THE FOURTH QUARTER OF 2018 AND ANALYSIS OF ITS OFF-LABEL USE (submitted in 2019)
	1ISG-004	ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE OF TREATMENT MULTIPLE MYELOMA (submitted in 2019)
	1ISG-005	ABC-VEN CROSSTAB ANALYSIS: A DECISION MAKING SYSTEM APPLIED FOR ANTICANCER MEDICINES (submitted in 2019)
	1ISG-006	EFFECTIVENESS EVALUATION OF HIGHCOST DRUGS FOR ADVANCED NON-SMALL-CELL LUNG CANCER: REAL WORLD EVIDENCE, COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION (submitted in 2019)
	1ISG-007	NEW CANCER DRUGS APPROVALS IN PORTUGAL (submitted in 2019)
	1ISG-008	COST EFFICACY ANALYSIS OF ABIRATERONE IN NEWLY DIAGNOSED HIGH RISK METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (submitted in 2019)
	1ISG-009	BUDGET IMPACT ANALYSIS OF A NATALIZUMAB EXTENDED INTERVAL DOSING REGIMEN (submitted in 2019)
	1ISG-010	INTRODUCTION OF RITUXIMAB BIOSIMILAR: AN OPPORTUNITY TO IMPROVE HEALTH SYSTEM EFFICIENCY? (submitted in 2019)
	1ISG-011	ASSESSMENT OF ASTHMA DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY AND RELATED COST IN THE VENETO REGION (submitted in 2019)
	1ISG-012	NATIONAL REPORTING SYSTEM FOR DRUG SHORTAGES : CLASSIFICATION AND TRENDS IN REPORTED CAUSES FROM 2015 TO 2018 (submitted in 2019)
	1ISG-013	SMARTPHONE APPLICATIONS FOR PATIENTS DIAGNOSED WITH GENITOURINARY TUMOURS: ANALYSIS OF THE QUALITY USING THE MOBILE APPLICATION RATING SCALE (submitted in 2019)
	1ISG-014	COST EFFECTIVENESS ANALYSIS OF PATIENTS' SELF-ADMINISTRATION OF MEDICATION (SAM) DURING HOSPITALISATION IN A CARDIOLOGY UNIT (submitted in 2019)
	1ISG-015	EVALUATION OF BISPECTRAL INDEX MONITORING IN GENERAL ANAESTHESIA THROUGH A HEALTH TECHNOLOGY ASSESSMENT METHOD: A POSSIBLE INTRODUCTION IN CLINICAL PRACTICE IN AN ITALIAN HOSPITAL? (submitted in 2019)
	1ISG-016	ENVISIONING SUSTAINABILITY IN PERSONALISED MEDICINE: FONDO AIFA 5% AND THE ITALIAN EXAMPLE (submitted in 2019)
	1ISG-017	IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE (submitted in 2019)
	1ISG-018	APPLICATION OF A TIME SLOT MODEL IN ONCOLOGY: DELIVERY PLANNING AND PROCESS OPTIMISATION (submitted in 2019)
	1ISG-019	HOSPITAL PHARMACISTS AGED <45 YEARS: AN EMPLOYMENT STATUS AND JOB SATISFACTION SURVEY IN ITALY (submitted in 2019)
	1ISG-020	COST SAVINGS IMPACT OF BIOSIMILARS: A LOCAL EXPERIENCE ON TRASTUZUMAB
	1ISG-021	INDIRECT COMPARISON OF BRIGATINIB VERSUS ALECTINIB IN THE ALK-POSITIVE NON-SMALL CELL LUNG CANCER
	1ISG-022	ECONOMIC ANALYSIS AFTER THE INCORPORATION OF BEVACIZUMAB BIOSIMILAR IN A THIRD LEVEL HOSPITAL
	1ISG-023	PHARMACOECONOMIC ANALYSIS OF REFERENCE BEVACIZUMAB: OPPORTUNITY FOR IMPROVED EFFICIENCY
	1ISG-024	BIOLOGICAL DRUGS IN THE TREATMENT OF IMMUNE MEDIATED INFLAMMATORY DISEASES: MONITORING OF PRESCRIPTION APPROPRIATENESS
	1ISG-025	BUDGET IMPACT ANALYSIS OF BIOSIMILAR ADALIMUMAB VERSUS REFERENCE ADALIMUMAB
	1ISG-026	MULTIDISCIPLINARY DOCTOR-PHARMACIST COLLABORATION IN THE MANAGEMENT OF REFUNDS POLICIES OF OPHTHALMIC DRUGS AT SANT'ANDREA HOSPITAL , VERCELLI
	1ISG-027	CARBON FOOTPRINT OF A STERILISATION UNIT
	1ISG-028	BECOMING OF GRADUATE HOSPITAL PHARMACISTS: A FRENCH NATIONAL SURVEY
	1ISG-029	CRANIOPLASTY: A REVIEW OF CUSTOMISED CRANIOPLASTY IMPLANTS
	1ISG-030	ECONOMIC IMPACT OF BIOLOGICAL MEDICINES ON A THIRD LEVEL HOSPITAL

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	IMPLEMENTATION OF HOME DELIVERY AND TELEPHARMACY SYSTEMS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	2SPD-002	IMPROVEMENT IN AN ANTIMICROBIAL STEWARDSHIP PROGRAMME AFTER IMPLEMENTING A SCREENING ALERT SYSTEM (submitted in 2019)
	2SPD-003	ECONOMIC IMPACT OF THE INTRODUCTION OF LAMIVUDINE PLUS DOLUTEGRAVIR BITHERAPY IN HIV NAIVE PATIENTS (submitted in 2019)
	2SPD-004	EFFICIENCY OF PRECISION DOSING WITH INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES (submitted in 2019)
	2SPD-005	ECONOMIC ANALYSIS OF OSIMERTINIB IN PREVIOUSLY UNTREATED EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (submitted in 2019)
	2SPD-006	ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML (submitted in 2019)
	2SPD-007	OUT OF SUPPLY OF CHEMOTHERAPY INJECTABLE MEDICINES OVER 9 MONTHS: PATIENT IMPACT (submitted in 2019)
	2SPD-008	IMPACT OF FRENCH EXPERIMENT FOR INCENTIVISING ETANERCEPT BIOSIMILAR USE AFTER 10 MONTHS (submitted in 2019)
	2SPD-009	COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB (submitted in 2019)
	2SPD-010	ECONOMIC IMPACT OF SWITCHING THE ADMINISTRATION ROUTE OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (submitted in 2019)
	2SPD-011	TRANS-INTERFACE GAIN SHARE PROGRAMME FOR BIOSSIMILAR INFLIXIMAB (submitted in 2019)
	2SPD-012	COST MINIMISATION STUDY IN SEVERE ASTHMA TREATMENT (submitted in 2019)
	2SPD-013	APPLICATION OF THE ABC ANALYSIS METHOD FOR OPTIMIZING THE STOCK MANAGEMENT OF MEDICAL DEVICES IN COMMON USE (submitted in 2019)
	2SPD-014	EVALUATING THE METHODOLOGICAL QUALITY OF PIVOTAL CLINICAL TRIALS´S PUBLICATIONS FOR ORPHAN DRUGS AUTHORISED IN 2018. ARE THEY RELIABLE? (submitted in 2019)
	2SPD-015	COST OF STOCKOUT. A GROWING PROBLEM (submitted in 2019)
	2SPD-016	FUTURE DISTRIBUTION MODELTS FOR PAID PHARMACEUTICALS: THE PATIENT'S PERSPECTIVE (submitted in 2019)
	2SPD-017	IMPACT OF THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE AT THE LISBON PORTUGUESE INSTITUTE OF ONCOLOGY (FG, EPE) (submitted in 2019)
	2SPD-018	FOUR YEAR STUDY OF DRUGS SHORTAGES IN TWO PUBLIC HOSPITALS (submitted in 2019)
	2SPD-019	FOUR YEARS OF SHORTAGES REGARDING THE ANATOMIC, THERAPEUTIC AND CHEMICAL CLASSIFICATION (submitted in 2019)
	2SPD-020	IMPACT OF MEDICINE SHORTAGES ON AN OUTPATIENT CLINIC OF A GENERAL HOSPITAL (submitted in 2019)
	2SPD-021	SURVEY OF DRUG SHORTAGES IN HUNGARIAN HOSPITALS (submitted in 2019)
	2SPD-022	DRUG SHORTAGES AND DRUG UNAVAILABILITY: ANALYSIS FROM AN ITALIAN HOSPITAL (submitted in 2019)
	2SPD-023	HOW MUCH DOES FALSIFIED MEDICINES DIRECTIVE ACTUALLY COSTS? DETAILED COST EVALUATION OF SERIALISATION IN A REPRESENTATIVE SAMPLE OF HUNGARIAN HOSPITAL PHARMACIES (submitted in 2019)
	2SPD-024	SHORTAGES OF MEDICINES IN HOSPITAL: RESULTS OF A SURVEY ON THE PERCEPTION OF HEALTH WORKERS IN THE WARDS VSV REAL WORLD (submitted in 2019)
	2SPD-025	APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE THE RISK LEVEL OF MEDICINE SHORTAGES (submitted in 2019)
	2SPD-026	MANAGEMENT OF DRUG SHORTAGES (submitted in 2019)
	2SPD-027	ECONOMIC IMPACT OF DRUG SHORTAGES (submitted in 2019)
	2SPD-028	REFERENCING A MIDLINE: HOW TO MAKE A CHOICE? (submitted in 2019)
	2SPD-029	OFF-LABEL DRUGS: USE ANALYSIS AND PHARMACOEPIDEMIOLOGY IN A COVID CENTRE IN ROME
	2SPD-030	POSITIONING OF DORAVIRINE IN THE PHARMACOTHERAPEUTIC GUIDE OF A THIRD LEVEL HOSPITAL.
	2SPD-031	SUBGROUP ANALYSIS ABOUT EFFICACY OF EARLY USE OF REMDESIVIR IN COVID-19
	2SPD-032	NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES IN UNTREATED METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER
	2SPD-033	EVALUATION OF DOCETAXEL IN LOW AND HIGH BURDEN METASTATIC HORMONE SENSITIVE PROSTATE CANCER
	2SPD-034	USE OF DARATUMUMAB BASED TREATMENTS IN PATIENTS WITH MULTIPLE MYELOMA AND HEPATIC IMPAIRMENT
	2SPD-035	BIOLOGICAL THERAPIES EFFECTIVENESS COMPARISON FOR PATIENTS WITH SEVERE-MODERATE PSORIASIS
	2SPD-036	CENTRALISED PROPOFOL RECONDITIONING PROCEDURE DURING COVID-19
	2SPD-037	ANALYSIS OF DRUG DISPENSES OUTSIDE THE HOSPITAL GUIDE IN A PSYCHIATRIC HOSPITAL
	2SPD-038	BEVACIZUMAB VERSUS RANIBIZUMAB IN OPHTHALMOLOGY OUTPATIENT SURGERY
	2SPD-039	MAKE OR BUY: PHARMACOECONOMIC EVALUATION OF GARGLE SOLUTIONS USED FOR SARS-CoV-2 SAMPLE COLLECTION
	2SPD-040	IMPACT OF AUTOMATED DISPENSING CABINETS ON DISPENSING ERRORS, INTERRUPTIONS AND PILLBOX PREPARATION TIME
	2SPD-041	QUANTITATIVE EVALUATION AND ECONOMIC IMPACT OF MEDICINE SHORTAGES IN A TEACHING HOSPITAL
	2SPD-042	MEDICAL DEVICE’S ACTIVE VIGILANCE OF THE PHARMACIST IN THE DIGITALISATION OF INTRAOCULAR LENSES (IOLs) LOGISTIC PATH
	2SPD-043	PROCEDURE FOR DELIVERY OF RETROCESSION DRUGS BY THE HOSPITAL PHARMACIST TO THE COMMUNITY PHARMACY DURING THE COVID-19 CRISIS: SATISFACTION SURVEY OF PHARMACIES
	2SPD-044	DruGhost: web based platform of drugs’ unavailability
	2SPD-045	OPTIMISATION OF THE BUYING PROCESS: BUILDING A TIME EARNING COMPARATOR TO EASE THE CHOICE BETWEEN EQUIVALENT SPECIALTIES
	2SPD-046	ORGANISATIONAL CHALLENGES OF THE PHARMACY SERVICE AS A CONSEQUENCE OF THE COVID-19 PANDEMIC
	2SPD-047	NEW REQUIREMENTS OF OUTPATIENTS IN THE COVID-19 ERA: ADAPTING PHARMACEUTICAL CARE
	2SPD-048	POLITICAL REPORT–OPTIONS TO BREAK THROUGH MEDICINE SHORTAGES

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	COMPATIBILITY AND STABILITY ASSESSMENT OF A SODIUM GLYCEROPHOSPHATE FORMULATION MIXED IN BAGS FOR NEONATAL TOTAL PARENTERAL NUTRITION (submitted in 2019)
	3PC-002	MICROBIOLOGICAL STABILITY TEST OF 15% TOPICAL RESORCINOL FOR QUALITY CONTROL (submitted in 2019)
	3PC-003	TERLIPRESSIN PH STABILITY FOR CONTINUOUS INFUSION (submitted in 2019)
	3PC-004	PHYSICOCHEMICAL STABILITY OF CEFEPIME IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019)
	3PC-005	PHYSICOCHEMICAL STABILITY OF CEFAZOLIN IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019)
	3PC-006	PHYSICOCHEMICAL STABILITY OF AZTREONAM IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATION FOR INTENSIVE CARE UNITS. (submitted in 2019)
	3PC-007	LEVOFLOXACIN 0.05 % EYEDROPS ELABORATION: A CASE OF STUDY (submitted in 2019)
	3PC-008	INTRAVENOUS PERFUSION OF CEFTOLOZANE-TAZOBACTAM USING ELASTOMERIC INFUSION PUMPS (submitted in 2019)
	3PC-009	TREATMENT OF RECURRENT OTOMYCOSIS WITH LOCAL APPLICATION OF A COMPOUNDED FORMULATION OF VORICONAZOLE EAR DROPS: CASE SERIES (submitted in 2019)
	3PC-010	EVALUATION OF THE PRODUCTION ACCURACY AND ERROR RATE IN THE AUTOMATED COMPOUNDING OF CYTOTOXIC PREPARATIONS BY A ROBOT (submitted in 2019)
	3PC-011	CLOSED SYSTEM TRANSFER DEVICE BASED ON AIR FILTRATION: THE DRUG VAPOUR CHALLENGE (submitted in 2019)
	3PC-012	MANAGEMENT OF NON-ADMINISTERED CHEMOTHERAPY PREPARATION: AN OPPORTUNITY TO MINIMISE DRUG WASTE IN ONCOLOGY PHARMACY (submitted in 2019)
	3PC-013	COMPARATIVE BIOPHYSICAL STABILITY STUDY OF ZIV-AFLIBERCEPT (ZALTRAP, OPENED VIALS) STORED AT 4ºC AND ROOM TEMPERATURE FOR 2 WEEKS (submitted in 2019)
	3PC-014	USE OF CABAZITAXEL AND REDUCTION OF WASTE: THE POTENTIAL OF DRUG-DAY. (submitted in 2019)
	3PC-015	SHORT TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY DARATUMUMAB (submitted in 2019)
	3PC-016	STABILITY OF COMPOUNDED NIVOLUMAB SOLUTION AFTER PNEUMATIC SYSTEM TRANSPORTATION (submitted in 2019)
	3PC-017	INCREASING PHARMACY PRODUCTIVITY BY EXPANDING THE ROLE OF THE INTRAVENOUS COMPOUNDING ROBOT IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019)
	3PC-018	MITOMYCIN C STABILITY ACCORDING TO PH AND TEMPERATURE CONDITIONS (submitted in 2019)
	3PC-019	IN USE PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY NIVOLUMAB (submitted in 2019)
	3PC-020	PHYSICOCHEMICAL STABILITY OF 25 MG/ML PEMETREXED DIARGININE IN PARTIALLY-USED VIALS AND 3 AND 12 MG/ML DILUTED IN DEXTROSE 5% IN POLYOLEFIN BAG. (submitted in 2019)
	3PC-021	STORAGE OF NIVOLUMAB, PEMBROLIZUMAB AND DARATUMUMAB FOR 14 DAYS AFTER COMPOUNDING IN THE HOSPITAL PHARMACY: A MICROBIOLOGICAL STABILITY STUDY (submitted in 2019)
	3PC-022	PARTICULATE QUALITY OF A CONTROLLED ATMOSPHERE AREA. COMPLIANCE WITH GOOD MANUFACTURING PRACTICES AT REST AND DURING ACTIVITY, HIGHLIGHTING OF FACTORS IMPACTING ON CONTAMINATION (submitted in 2019)
	3PC-023	DEVELOPMENT AND VALIDATION OF A DISCRIMINATIVE METHOD FOR ANTHRACYCLINES DRUGS USED IN ONCOLOGY BY VISIBLE SPECTROMETER (submitted in 2019)
	3PC-024	THE EFFECTS OF FREEZE-THAW CYCLING ON THE STABILITY OF THE ADALIMUMAB BIOSIMILAR SB5 (submitted in 2019)
	3PC-025	MAGISTRAL FORMULATION FOR A PATIENT WITH MULTIPLE FOOD ALLERGY (submitted in 2019)
	3PC-026	FORMULATION AND GALENIC CHARACTERISATION OF A TACROLIMUS ADHESIVE GEL FOR TREATMENT OF ULCERATIVE PROCTITIS (submitted in 2019)
	3PC-027	LONG TERM STABILITY OF A READY TO USE TOPICAL ANAESTHETIC GEL KIT (submitted in 2019)
	3PC-028	COMPOUNDING AN ORAL LIQUID FORMULATION OF DIAZEPAM ALCOHOL FREE (submitted in 2019)
	3PC-029	PAEDIATRIC DRUG RESISTANT EPILEPSY: NITRAZEPAM 1MG/ML SOLUTIONS TO AVOID CLINICAL THERAPEUTIC ERROR (submitted in 2019)
	3PC-030	ANALYTICAL METHOD VALIDATION TO CARRY OUT PHYSICOCHEMICAL STABILITY STUDIES OF METHADONE ORAL SOLUTIONS. (submitted in 2019)
	3PC-031	CURRENT STATE OF THE ANTI-INFECTIVE OPHTHALMIC COMPOUNDING FORMULATION IN PHARMACY SERVICES: A NATIONAL SURVEY (submitted in 2019)
	3PC-032	AUTOLOGOUS TISSUE ADHESIVE IN OPHTHALMOLOGICAL SURGERY (submitted in 2019)
	3PC-033	INTRACAMERAL AND INTRASTROMAL VORICONAZOLE ADMINISTRATION IN FUSARIUM KERATITIS (submitted in 2019)
	3PC-034	CONTENT UNIFORMITY OF EXTEMPORANEOUS COMPOUNDED SUSPENSIONS (submitted in 2019)
	3PC-035	93% OXYGEN SELF-PRODUCTION: EXPERIENCE IN NA ITALIAN HOSPITAL (submitted in 2019)
	3PC-036	CASE STUDY: DEVELOPMENT OF AN OINTMENT ACCORDING TO THE PHARMACEUTICAL INSPECTION CONVENTION GUIDELINE (submitted in 2019)
	3PC-037	STERILITY OF SINGLE USE VIALS WHEN ACCESSED USING A CLOSED SYSTEM TRANSFER DEVICE (submitted in 2019)
	3PC-038	PHYSICOCHEMICAL STABILITY OF THE BEVACIZUMAB BIOSIMILAR, ABP 215, IN INTRAVENOUS BAGS AFTER PREPARATION AND STORAGE (submitted in 2019)
	3PC-039	OPTIMISATION OF MIXING AN ORAL POWDER MIXTURE OF CODEINE PREPARED IN THE HOSPITAL PHARMACY FOR FILLING INTO HARD CAPSULES (submitted in 2019)
	3PC-040	GALENIC VALIDATION OF A DEXAMETHASONE 0.01% MOUTHWASH SOLUTION TO PREVENT EVEROLIMUS RELATED STOMATITIS (submitted in 2019)
	3PC-041	SURFACE CONTAMINATION WITH CYTOTOXIC DRUGS IN EUROPEAN HOSPITAL WARDS (submitted in 2019)
	3PC-042	THE SIGNIFICANCE OF PHARMACY PREPARATION IN PAEDIATRICS: MAKING INDIVIDUAL THERAPIES FOR CRITICALLY ILL CHILDREN POSSIBLE (submitted in 2019)
	3PC-043	HAZARDOUS DRUGS: IMPACT OF MEASURES FOR SAFE HANDLING (submitted in 2019)
	3PC-044	IN USE PHYSICOCHEMICAL STABILITY OF PEMBROLIZUMAB UNDER THE DILUTION CONDITION REQUIRED FOR USE IN A DAY HOSPITAL (submitted in 2019)
	3PC-045	IMPACT OF THE PREPARATION OF A CLINICAL SOLUTION OF RITUXIMAB 1.0 MG/ML ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: SODIUM CHLORIDE AND GLUCOSE CONCENTRATION, AND AGITATION EFFECT (submitted in 2019)
	3PC-046	PARENTERAL NUTRITION ADMIXTURES: REVIEW OF THE MICROBIOLOGICAL SAMPLING PLAN (submitted in 2019)
	3PC-047	STUDY OF THE TRIGON DEPOT ALLERGY TEST (TRIAMCINOLONE AND EXCIPIENTS: CARBOXYMETHYLCELLULOSE, POLYSORBATE 80) DEVELOPED IN THE PHARMACY DEPARTMENT (submitted in 2019)
	3PC-048	IMPORTANCE OF NON-STERILE FORMULATION IN A PAEDIATRIC HOSPITAL (submitted in 2019)
	3PC-049	IMIPENEM-CILASTATIN FORTIFIED EYE DROPS FOR THE TREATMENT OF CORNEAL ULCERS CAUSED BY: CONTACT LENSES. DEVELOPMENT AND CHARACTERISATION (submitted in 2019)
	3PC-050	IMPORTANCE OF COMPOUNDING IN THE PAEDIATRIC HOSPITAL PHARMACY (submitted in 2019)
	3PC-051	CIRCUIT TO PREPARE AND CONDITION ORAL HAZARDOUS MEDICINES (submitted in 2019)
	3PC-052	HAZARDOUS MEDICINES IN A PAEDIATRIC HOSPITAL (submitted in 2019)
	3PC-053	IMPACT OF SERIALISATION ON RECEPTION OF MEDICINES AND ACTIVITY SMOOTHING (submitted in 2019)
	3PC-054	SODIUM BENZOATE SUSPENSION IN NON-KETOTIC HYPERGLYCINAEMIA: A CASE REPORT (submitted in 2019)
	3PC-055	STABILITY OF UROKINASE IN CITRATE BASED SOLUTIONS
	3PC-056	A STABLE READY-TO-USE FORMULATION OF PHENYLEPHRINE HCL IN SYRINGES
	3PC-057	USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY
	3PC-058	PHYSICOCHEMICAL STABILITY OF MEROPENEM IN POLYPROPYLENE SYRINGES AT 41.7 mg/mL FOR INTENSIVE CARE UNITS
	3PC-059	PHYSICOCHEMICAL STABILITY OF CEFTOLOZANE/TAZOBACTAM IN POLYPROPYLENE SYRINGES AT 61.5/31.25 mg/mL AND IN ELASTOMERIC DEVICES AT 25.0/12.5 mg/mL
	3PC-060	PHYSICOCHEMICAL STABILITY OF VANCOMYCIN SOLUTION IN ELASTOMERIC DEVICES AT 37.5 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER
	3PC-061	PHYSICOCHEMICAL STABILITY OF CLOXACILLIN SOLUTION IN POLYPROPYLENE SYRINGES AT 125 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER
	3PC-062	IMPACT OF THE PREPARATION OF THE 1.0 MG/ML NIVOLUMAB CLINICAL SOLUTION ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: NaCl AND GLUCOSE CONCENTRATION AND AGITATION EFFECT
	3PC-063	PERFORMANCE QUALIFICATION OF ROBOTIC SYSTEM FOR CYTOTOXIC DRUG PREPARATION IN A FULLY GMP COMPLIANT HOSPITAL PHARMACY
	3PC-064	A MULTICENTRE STUDY COMPARING CHEMOTHERAPY PREPARATIONS USING A DIGITAL VIDEO MONITORING
	3PC-065	IMPACT OF LIGHT STRESS ON THE ISOFORM PROFILE OF NIVOLUMAB (OPDIVO) IN OPENED VIALS ESTIMATED BY (RP)UHPLC-UV-(HESI/ORBITRAP)-MS
	3PC-066	COMPOUNDING AN EYE DROP FORMULATION OF TOPICAL INSULIN FOR CORNEAL DEFECTS REFRACTORY TO PREVIOUS TREATMENT: EXPERIENCE IN REAL CLINICAL PRACTICE
	3PC-067	KEY ROLE OF HOSPITAL PHARMACY IN A NON-PROFIT STUDY INVOLVING RUXOLITINIB 5mg CPS: IMPLEMENTATION AND QUALITY ASSURANCE OF AN INVESTIGATIONAL MANUFACTURING PRODUCT
	3PC-068	LONG TERM STABILITY OF CO-ADMINISTRATION OF BUMETANIDE AND SCOPOLAMINE FOR THE PALLIATIVE CARE UNIT
	3PC-069	IMPROVING SAFETY AND QUALITY FOR ASEPTIC TRANSFER PROCEDURES IN HOSPITAL PHARMACIES
	3PC-070	EVALUATION OF COMPATIBILITY OF ACETYLSALICYLIC ACID AND ATENOLOL WITH MEDICATIONS COMMONLY USED IN INTENSIVE CARE UNITS
	3PC-071	FULLY AUTOMATED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS): A 12 MONTH ANALYSIS OF PERFORMANCES AND IMPACT OF COVID-19 ON STERILE ANTIBIOTICS PRODUCTION
	3PC-072	WHICH MODEL TO ESTIMATE AT BEST THE THEORETICAL OSMOLARITY OF NOMINATIVE PARENTERAL NUTRITION?
	3PC-073	EVALUATION OF ANTIOBIOTICS' PHYSICOCHEMICAL INCOMPATIBILITY WITH THE PRESENCE OF DIVALENT CATIONS

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	EXPERIENCE WITH THE NEW DIRECT ACTING ANTIVIRAL AGENTS IN A THIRD LEVEL HOSPITAL IN 2018 (submitted in 2019)
	4CPS-002	ANTICHOLINERGIC BURDEN IN CONSTIPATED PATIENT ADMITTED TO AN EMERGENCY DEPARTMENT (submitted in 2019)
	4CPS-003	LIRAGLUTIDE IN CHRONIC INTESTINAL FAILURE: OVERVIEW AND CASE REPORT (submitted in 2019)
	4CPS-004	EVALUATION OF THE USE OF HYDROCORTISONE, VITAMIN C AND THIAMINE FOR THE TREATMENT OF SEPTIC SHOCK (submitted in 2019)
	4CPS-005	RISK FACTORS FOR PERSISTENCE AND TOLERANCE OF COW'S MILK ALLERGY (submitter in 2019)
	4CPS-006	USE OF AMMONIUM TETRATHIOMOLYBDATE IN WILSON DISEASE (submitted in 2019)
	4CPS-007	PHARMACEUTICAL CARE AS A MEANS OF PREVENTION AGAINST DRUG IATROGENESIS: CASE OF ORAL ANTICOAGULANTS (submitted in 2019)
	4CPS-008	RISK FACTORS ASSOCIATED WITH RE-ADMISSION TO THE EMERGENCY DEPARTMENT, IN PATIENTS WITH PREVIOUS GASTROINTESTINAL HAEMORRHAGE SECONDARY TO ORAL ANTICOAGULANT THERAPY (submitted in 2019)
	4CPS-009	DURATION OF DUAL ANTIPLATELET THERAPY IN CORONARY ARTERY DISEASE: IS PHARMACIST INTERVENTION NECESSARY TO IMPROVE PATIENT SAFETY? (submitted in 2019)
	4CPS-010	SAFETY AND EFFICACY OF LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS WITH PORTAL VEIN THROMBOSIS (submitted in 2019)
	4CPS-011	PRESCRIPTION ANALYSIS OF DIRECT ACTING ORAL ANTICOAGULANTS (submitted in 2019)
	4CPS-012	AUDIT OF ORAL ANTICOAGULANT PRESCRIBING; WHAT HAS CHANGED IN 4 YEARS? (submitted in 2019)
	4CPS-013	EFFECT OF 2MG INTRAVENOUS PHYTONADIONE TREATMENT ON INTERNATIONAL NORMALISED RATIO IN THE HOSPITALISED ADULT (submitted in 2019)
	4CPS-014	CLINICAL AND ASSISTED IMPACT OF ISCHAEMICAL ICTUS IN PATIENTS TREATED WITH ORAL ANTICOAGULANTS (submitted in 2019)
	4CPS-015	SITUATIONAL ANALYSIS OF POSTOPERATIVE IRON SUPPLEMENTATION PRESCRIPTIONS IN A PLASTIC SURGERY DEPARTMENT (submitted in 2019)
	4CPS-016	INAPPROPRIATE USE OF HUMAN ALBUMIN IN A TEACHING HOSPITAL (submitted in 2019)
	4CPS-017	EFFICACY AND SAFETY OF TOLVAPTAN IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (submitted in 2019)
	4CPS-018	EFFICACY OF UREA IN THE TREATMENT OF HYPONATRAEMIA IN SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (submitted in 2019)
	4CPS-019	ALIROCUMAB AND EVOLOCUMAB: EFFECTIVENESS AFTER 3 YEARS OF FOLLOW-UP IN A REAL WORLD SETTING (submitted in 2019)
	4CPS-020	USE, EFFICACY AND ADHERENCE TO TREATMENT WITH PCKS9 INHIBITORS IN REAL CLINICAL PRACTICE (submitted in 2019)
	4CPS-021	ALIROCUMAB AND EVOLOCUMAB: RESULTS IN CLINICAL PRACTICE. (submitted in 2019)
	4CPS-022	PCSK9 INHIBITORS: EVALUATION OF EFFECTIVENESS IN OUR CENTRE IN RELATION TO THE OFFICIAL CLINICAL ENDPOINTS (submitted in 2019)
	4CPS-023	LONG-TERM EFFICACY, SAFETY AND ADHERENCE TO ALIROCUMAB IN PATIENTS WITH DYSLIPIDAEMIA FROM A TERTIARY HOSPITAL COHORT (submitted in 2019)
	4CPS-024	EFFECTIVENESS OF ANTI-INTERLEUKIN-17 DRUGS IN PSORIASIS IN CLINICAL PRACTICE (submitted in 2019)
	4CPS-025	DUPILUMAB IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS: CASE REPORTS (submitted in 2019)
	4CPS-026	DALBAVANCIN OFF-LABEL USE: EFFECTIVENESS AND SAFETY (submitted in 2019)
	4CPS-027	ANTIBIOTIC THERAPY REASSESSMENT AND ITS DOCUMENTATION: CAN VIRTUAL TOOLS IMPROVE PRACTICES? (submitted in 2019)
	4CPS-028	EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-029	PRELIMINARY RESULTS OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN ONCOLOGY DEPARTMENT (submitted in 2019)
	4CPS-030	INCIDENCE AND RISK FACTORS FOR PROSTHETIC JOINT INFECTION WITHIN 90 DAYS AFTER HEMIARTHROPLASTY FOR FEMORAL NECK FRACTURES IN THE ELDERLY (submitted in 2019)
	4CPS-031	AUDIT OF ANTIBIOTIC PROPHYLAXIS PRACTICE IN VISCERAL SURGERY IN AN AFRICAN COUNTRY (submitted in 2019)
	4CPS-032	ANTIBIOTIC PRESCRIPTION THROUGH MOTIVATED REQUEST: CLINICAL PHARMACY TOOL TO IMPROVE APPROPRIATENESS AND LIMIT RESISTANT BACTERIAl STRAINS. A FOLLOW-UP AFTER A YEAR OF MONITORING IN A LOCAL HOSPITAL (submitted in 2019)
	4CPS-033	OFF-LABEL USE OF NEBULISED AZTREONAM LYSINE IN PATIENTS WITH CHRONIC GRAM-NEGATIVE BACTERIAL LUNG COLONISATION (submitted in 2019)
	4CPS-034	IS IT POSSIBLE TO RATIONALISE THE ANTIBIOTIC USE AMONG HOSPITALISED PATIENTS BY CLINICAL PHARMACISTS’ ACTIVITY? (submitted in 2019)
	4CPS-035	CLINICAL PHARMACOKINETICS OF VANCOMYCIN IN NEUTROPENIC PATIENTS (submitted in 2019)
	4CPS-036	PHARMACEUTICAL INTERVENTIONS IN A SMALL HOSPITAL (submitted in 2019)
	4CPS-037	CLINICAL OUTCOME IN PAEDIATRIC INTENSIVE CARE UNIT PATIENTS TREATED WITH VANCOMYCIN (submitted in 2019)
	4CPS-038	STABILITY TO HIGH TEMPERATURES OF THE ANTIMICROBIALS USED IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY PROGRAMMES (submitted in 2019)
	4CPS-039	NOSOCOMIAL INFECTION BY MULTIRESISTANT PATHOGENS IN KIDNEY TRANSPLANTED PATIENTS (submitted in 2019)
	4CPS-040	ADEQUACY OF ANTIBIOTIC PRESCRIPTIONS IN A NURSING HOME (submitted in 2019)
	4CPS-041	PHARMACIST LED ANTIMICROBIAL STEWARDSHIP PROGRAMME (submitted in 2019)
	4CPS-042	PHARMACIST'S MISSION IN INFECTION MANAGEMENT : EVALUATION OF IMPROVEMENT ACTIONS (submitted in 2019)
	4CPS-043	EFFECTIVENESS OF A NEW INTERNAL PROTOCOL FOR DOSAGE OF VANCOMYCIN IN NEONATES (submitted in 2019)
	4CPS-044	THE ROUTINE USE OF ANTIBIOTICS AFTER INSERTION OF A CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED): EVIDENCE AND CURRENT PRACTICE (submitted in 2019)
	4CPS-045	COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS (submitted in 2019)
	4CPS-046	MONITORING THE PRESCRIPTION OF NEW ANTIBIOTICS: THE WORK OF THE ANTIMICROBIAL STEWARDSHIP TEAM IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-047	ASSESSING THE IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS: ROLE OF HOSPITAL PHARMACISTS. (submitted in 2019)
	4CPS-048	BETA-LACTAM ANTIBIOTICS IN CRITICAL ILL PATIENTS: ARE WE DOSING CORRECTLY OUR PATIENTS CORRECTLY? (submitted in 2019)
	4CPS-049	UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM? (submitted in 2019)
	4CPS-050	CONFORMITY OF ANTIBIOTIC THERAPY DURATION IN PATIENTS WITH FEBRILE NEUTROPENIA, HOSPITALISED IN THE HAEMATOLOGY DEPARTMENT OF A UNIVERSITY HOSPITAL (submitted in 2019)
	4CPS-051	ANTIBIOTICS IN THE EMERGENCY DEPARTMENT: IS IT POSSIBLE TO IMPROVE THE PRESCRIPTIONS FOR INFECTIOUS RESPIRATORY DISEASES IN AMBULATORY PATIENTS? (submitted in 2019)
	4CPS-052	EVALUATION OF PIPERACILIN/TAZOBACTAM DOSAGE IN SEPTIC PATIENTS ATTENDING THE EMERGENCY DEPARTMENT (submitted in 2019)
	4CPS-053	ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN INTENSIVE CARE UNIT (submitted in 2019)
	4CPS-054	A MULTIDISCIPLINARY AND EDUCATIONAL APPROACH TO ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN THE EMERGENCY DEPARTMENT (submitted in 2019)
	4CPS-055	EVALUATION OF USE, EFFECTIVENESS AND SAFETY OF ISAVUCONAZOL (submitted in 2019)
	4CPS-056	PROPER USE OF ANTIFUNGALS: IMPLEMENTATION OF OPERATIONAL MULTIDISCIPLINARY TEAMS DEDICATED TO ANTIFUNGALS (submitted in 2019)
	4CPS-057	THERAPEUTIC DRUG MONITORING OF VORICONAZOLE (submitted in 2019)
	4CPS-058	MANAGEMENT OF THE HOSPITALISED PATIENT WITH FLU (submitted in 2019)
	4CPS-059	STRATEGY FOR CHANGE IN ANTIRETROVIRAL THERAPY: LOOKING FOR BETTER RESULTS (submitted in 2019)
	4CPS-060	PRESCRIPTION ANALYSIS OF TENOFOVIR DISPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE FUMARATE IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-061	ADHERENCE TO ANTIRETROVIRAL TREATMENT AS A FUNCTION OF THE COMPLEXITY OF THE TREATMENT (submitted in 2019)
	4CPS-062	PATIENTS WITH DARUNAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE TREATMENT IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-063	USE OF OSELTAMIVIR IN THE TREATMENT OF INFLUENZA A (submitted in 2019)
	4CPS-064	ADHERENCE TO ANTIRETROVIRAL TREATMENT IN PATIENTS WITH HIV (submitted in 2019)
	4CPS-065	SWITCHING TO EQUIVALENT ALTERNATIVES: ANTIRETROVIRAL OPTIMISATION STRATEGY (submitted in 2019)
	4CPS-066	CHANGING FROM COBICISTAT TO A RITONAVIR BOOSTED REGIMEN IN HIV POSITIVE PATIENTS (submitted in 2019)
	4CPS-067	ANALYSIS OF USAGE OF DIRECT ACTIN ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C. (submitted in 2019)
	4CPS-068	EFFECTIVENESS OF DOLUTEGRAVIR AND LAMIVUDINE THERAPY IN A TWO DRUG REGIMEN IN A THIRD LEVEL HOSPITAL. (submitted in 2019)
	4CPS-069	EVALUATION OF PALIVIZUMAB AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION (submitted in 2019)
	4CPS-070	ANALYSIS OF THE USE OF NON-SPECIFIC INTRAVENOUS IMMUNOGLOBULINS IN A TERTIARY HOSPITAL. (submitted in 2019)
	4CPS-071	ANALYSIS OF EFFECTIVENESS: USE OF PERTUZUMAB AND TRASTUZUMAB IN NEOADJUVANT TREATMENT IN PATIENTS WITH HER2 POSITIVE BREAST CANCER AND ITS CORRELATION WITH PLASMA LEVELS OF TRASTUZUMAB (submitted in 2019)
	4CPS-072	COMPARISON OF IMMUNE CHECKPOINT INHIBITORS (NIVOLUMAB, PEMBROLIZUMAB, ATÉZOLIZUMAB AND DURVALUMAB) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: TOLERANCE AND FINANCIAL IMPACT (submitted in 2019)
	4CPS-073	EFFECTIVENESS AND SAFETY OF PLATIN/PERMETREXED COMBINATION IN NON-SMALL CELL LUNG CANCER. (submitted in 2019)
	4CPS-074	CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER: POTENTIAL DRUG INTERACTIONS (submitted in 2019)
	4CPS-075	IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION: INCIDENCE AND MANAGEMENT IN THE REAL LIFE CLINICAL SETTING (submitted in 2019)
	4CPS-076	INDIRECT COMPARISON BETWEEN PEMBROLIZUMAB MONOTHERAPY AND PEMBROLIZUMAB CHEMOTHERAPY REGIMENE IN SQUAMOUS LUNG CANCER (submitted in 2019)
	4CPS-077	DETECTION AND COMMUNICATION OF CONCOMITANT USE OF CAPECITABINE AND PROTON PUMP INHIBITORS (submitted in 2019)
	4CPS-078	EFFECTIVENESS AND SAFETY OF ERIBULIN FOR ADVANCED BREAST CANCER TREATMENT (submitted in 2019)
	4CPS-079	SEQUENCING OF IBRUTINIB, IDELALISIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019)
	4CPS-080	REAL LIFE TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (submitted in 2019)
	4CPS-081	GEFITINIB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY. (submitted in 2019)
	4CPS-082	RISK OF MYELOTOXICITY IN NON-CANCER PATIENTS TREATED WITH CHEMOTHERAPY (submitted in 2019)
	4CPS-083	SAFETY AND TOLERABILITY OF PALBOCICLIB IN CLINICAL PRACTICE IN A TERTIARY HOSPITAL (submitted in 2019)
	4CPS-084	ANTHRACYCLINES DOSAGE IN PAEDIATRIC OBESE PATIENTS (submitted in 2019)
	4CPS-085	IMPROVED ACCESS TO CHEMOTHERAPEUTIC TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (submitted in 2019)
	4CPS-086	IMATINIB DOSE OPTIMISATION THROUGH THERAPEUTIC MONITORING IN CHRONIC MYELOID LEUKAEMIA AS PART OF PHARMACEUTICAL CARE (submitted in 2019)
	4CPS-087	OPTIMISATION OF RESOURCES IN THE USE OF IMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB IN WEIGHT-BASED DOSING INSTEAD OF FLAT DOSE. (submitted in 2019)
	4CPS-088	CHECKPOINT INHIBITORS IN NON-MICROCYTIC LUNG CANCER: RESULTS IN COMMON CLINICAL PRACTICE (submitted in 2019)
	4CPS-089	COMPARATIVE EFFECTIVENESS OF NINTEDANIB PLUS DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN ADENOCARCINOMA NON-SMALL CELL LUNG CANCER (submitted in 2019)
	4CPS-090	EFFICACY AND SAFETY OF ERLOTINIB IN NON-SMALL CELL LUNG CANCER (submitted in 2019)
	4CPS-091	EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH PANCREATIC CANCER (submitted in 2019)
	4CPS-092	EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH METASTATIC NON-MICROCYTIC LUNG CANCER (submitted in 2019)
	4CPS-093	EFFECTIVENESS OF DEXAMETHASONE MOUTHWASH 0.1MG/ML FOR PREVENTION OF EVEROLIMUS RELATED STOMATITIS (submitted in 2019)
	4CPS-094	CHARACTERISATION OF POTENTIAL DRUG-DRUG INTERACTIONS IN ONCOLOGICAL PATIENTS TREATED WITH ORAL ANTICANCER DRUGS (submitted in 2019)
	4CPS-095	REVIEWING THE LATEST CLINICAL RESEARCH FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER: SELECTION OF RANDOMISED CONTROLLED TRIALS PUBLISHED IN 2018 (submitted in 2019)
	4CPS-096	EVALUATION OF CLINICAL PHARMACY SERVICES IN A HAEMATOLOGY OUTPATIENT SETTING. (submitted in 2019)
	4CPS-097	SECOND LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS (submitted in 2019)
	4CPS-098	INDIRECT TREATMENT COMPARISONS OF IBRUTINIB-OBINOTUZUMAB VERSUS VENETOCLAX-OBINOTUZUMAB IN NAIVE CHRONIC LYMPHOCYTIC LEUKAEMIA (submitted in 2019)
	4CPS-099	REAL WORLD EVIDENCE OF PEMBROLIZUMAB AS MONOTHERAPY IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY STUDY (submitted in 2019)
	4CPS-100	ANTHRACYCLINE DOSING IN OBESE ADULT PATIENTS: A SYSTEMATIC REVIEW (submitted in 2019)
	4CPS-101	TRIFLURIDINE-TIPIRACIL FOR METASTATIC COLORECTAL CANCER: REAL WORLD DATA EXPERIENCE (submitted in 2019)
	4CPS-102	INFLUENCE OF PALBOCICLIB TOXICITY IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019)
	4CPS-103	IS THERE A ROLE FOR THE PHARMACIST IN SCREENING FOR METABOLIC SYNDROME? (submitted in 2019)
	4CPS-104	SWITCHING ORAL ANTIANDROGENIC TREATMENT IN PATIENTS WITH CASTRATE METASTATIC PROSTATE CANCER: AN ANALYSIS. (submitted in 2019)
	4CPS-105	TOLERANCE PROFILE TO ANTI-THYMOCYTE IMMUNOGLOBULIN TREATMENT AND ITS RELATION TO INFECTIOUS PARAMETERS IN PAEDIATRIC PATIENTS (submitted in 2019)
	4CPS-106	ANALYSIS OF THE PRESCRIPTION AND SAFE DRUG ADMINISTRATION OF OCRELIZUMAB (submitted in 2019)
	4CPS-107	IMPACT OF A TOOL IN THE ELECTRONIC CLINICAL HISTORY FOR THE OPTIMISATION OF BIOLOGIC DRUGS IN RHEUMATOLOGY (submitted in 2019)
	4CPS-108	A REVIEW OF INFLIXIMAB BIOSIMILAR TO BIOSIMILAR SWITCH: REMSIMA TO FLIXABI (submitted in 2019)
	4CPS-109	ANALYSIS OF CHANGES IN DISEASE MODIFYING TREATMENT IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS (submitted in 2019)
	4CPS-110	VEDOLIZUMAB: OUTCOMES AND THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
	4CPS-111	CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS NAÏVE AND SWITCHED PATIENTS: AFTER 5 YEARS OF FOLLOW-UP (submitted in 2019)
	4CPS-112	ADHERENCE TO ADALIMUMAB, GOLIMUMAB AND USTEKINUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
	4CPS-113	INOTUZUMAB OZOGAMIZIN FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT PATIENT: A CASE REPORT. (submitted in 2019)
	4CPS-114	BELIEFS ABOUT MEDICATION AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB (submitted in 2019)
	4CPS-115	THERAPEUTIC DRUG MONITORING OF ETANERCEPT BIOSIMILAR IN PSORIATIC PATIENTS (submitted in 2019)
	4CPS-116	TEN YEARS OF EXPERTISE IN USTEKINUMAB USE FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS (submitted in 2019)
	4CPS-117	CASE REPORT: USEFULNESS OF THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN MANAGING ACUTE GRAFT VERSUS HOST DISEASE (submitted in 2019)
	4CPS-118	REAL CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS OF IMMUNOSUPPRESSANTS IN TRANSPLANT PATIENTS. (submitted in 2019)
	4CPS-119	“REAL WORLD” EXPERIENCE OF TOFACITINIB AND BARICITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: EFFECTIVENESS AND SAFETY EVALUATION (submitted in 2019)
	4CPS-120	TEN YEAR ANALYSIS OF THE USE OF INFLIXIMAB IN ULCERATIVE COLITIS (submitted in 2019)
	4CPS-121	EVALUATION OF COST AND EFFICACY OF ECULIZUMAB IN COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY IN THE CLINICAL SETTING (submitted in 2019)
	4CPS-122	POTENTIAL OPTIMISATION OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE (submitted in 2019)
	4CPS-123	EVALUATION OF ADHERENCE TO ORAL DISEASE MODIFYING THERAPIES (ORAL-DMT) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (submitted in 2019)
	4CPS-124	ADHERENCE TO SELECTIVE IMUNOSUPPRESSIVE DRUGS TREATMENTS IN PATIENTS WITH INFLAMMATORY IMMUNE-MEDIATED DISEASES (submitted in 2019)
	4CPS-125	ACCEPTANCE OF PHARMACOKINETIC RECOMMENDATIONS FOR EVEROLIMUS IN RENAL TRANSPLANT PATIENTS (submitted in 2019)
	4CPS-126	A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWOL DISEASE: A PRELIMINARY ANALYSIS (submitted in 2019)
	4CPS-127	ECONOMIC IMPACT OF INTENSIFICATION REGIMENS IN INFLAMMATORY BOWEL DISEASE (submitted in 2019)
	4CPS-128	LIVER TRANSPLANT AND DIABETES MELLITUS (submitted in 2019)
	4CPS-129	PILOT STUDY TO SURVEY THE ATTITUDE, SUPPLEMENT USE AND STORAGE CONDITIONS OF DRUG PRODUCTS AMONG PATIENTS RECEIVING BIOLOGICAL THERAPY (submitted in 2019)
	4CPS-130	ONE IN A MILLION: A TNF RECEPTOR-1 ASSOCIATED SYNDROME RESISTANT TO ANTI-TNF-ALPHA THERAPY. (submitted in 2019)
	4CPS-131	EFFECTIVENESS OF NUSINERSEN IN PAEDIATRIC PATIENTS SMA1 AND SMA2 (submitted in 2019)
	4CPS-132	INDIRECT TREATMENT COMPARISON OF ANTICALCITONIN GENE RELATED PEPTIDE PATHWAY ANTIBODIES IN CHRONIC MIGRAINE (submitted in 2019)
	4CPS-133	IS PARACETAMOL A REAL ALTERNATIVE IN THE MANAGEMENT OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS? (submitted in 2019)
	4CPS-134	PREVALENCE ANALYSIS OF PATIENTS TREATED WITH TRIPTANS AT RISK OF DEVELOPING MEDICATION OVERUSE HEADACHE AND DEVELOPMENT OF A PRESCRIPTION OPTIMISATION STRATEGY. (submitted in 2019)
	4CPS-135	PERPHENAZINE AND PROPRANOLOL POISONING: A CASE REPORT. (submitted in 2019)
	4CPS-136	DEXMEDETOMIDINE TREATMENT FOR THE SEDATION OF PRETERM NEONATES (submitted in 2019)
	4CPS-137	REVIEW OF 3 MONTH PRESCRIPTIONS CONTAINING DRUGS INDUCING QT PROLONGATION AND TORSADE DE POINTE (submitted in 2019)
	4CPS-138	AN OBSERVATIONAL RETROSPECTIVE STUDY ON TREATMENT ADHERENCE OF LONG ACTING INJECTABLE ANTIPSYCHOTICS (submitted in 2019)
	4CPS-139	PSYCHOTROPIC DRUG USAGE IN OCTOGENARIAN AND NONAGENARIAN COMPLEX CHRONIC PATIENTS (submitted in 2019)
	4CPS-140	CURRENT STATUS OF CLINICAL TRIALS FOR ALZHEIMER’S DISEASE (submitted in 2019)
	4CPS-141	EFFECTIVENESS OF IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA (submitted in 2019)
	4CPS-142	EFFECTIVENESS AND SAFETY OF ANTI-IL-5 BIOLOGIC AGENTS IN SEVERE EOSINOPHILIC ASTHMA (submitted in 2019)
	4CPS-143	TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTION PULMONARY DISEASE: ARE OUR HOSPITAL NURSES AND PHYSICIANS READY TO TREAT AND EDUCATE IN-PATIENTS? (submitted in 2019)
	4CPS-144	SAFETY AND EFFECTIVENESS OF REDUCED DOSE OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA (submitted in 2019)
	4CPS-145	EVALUATION OF A PHARMACEUTICAL CARE PROGRAMME FOR PATIENTS BEING TREATED WITH OMALIZUMAB (submitted in 2019)
	4CPS-146	EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN THE TREATMENT OF SEVERE UNCONTROLLED ASTHMA (submitted in 2019)
	4CPS-147	THERAPEUTIC POSITIONING AND USE OF INTRAVITREAL RANIBIZUMAB AND AFLIBERCEPT (submitted in 2019)
	4CPS-148	CLINICAL EVALUATION AND SATISFACTION OF PATIENTS TREATED WITH PRGF-ENDORET (PLASMA RICH IN GROWTH FACTORS) (submitted in 2019)
	4CPS-149	INITIAL THERAPY FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION: ARE THE GUIDELINES MET IN CLINICAL PRACTICE? (submitted in 2019)
	4CPS-150	ASSESSMENT OF BURDEN OF DISEASE IN TERMS OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (submitted in 2019)
	4CPS-151	THE IMPACT OF AN INTEGRATED ELECTRONIC MEDICAL RECORD ON THERAPEUTIC DRUG MONITORING (submitted in 2019)
	4CPS-152	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN THE EXCHANGE OF THERAPEUTIC EQUIVALENTS (submitted in 2019)
	4CPS-153	INTENSIFICATION IN BIOLOGICAL TREATMENT IN ULCERATIVE COLITIS (submitted in 2019)
	4CPS-154	POTENTIALLY INAPPROPRIATE MEDICATION FOR ELDERLY HOSPITALISED PATIENTS IN A TRAUMA AND ORTHOPAEDIC SURGERY DEPARTMENT (submitted in 2019)
	4CPS-155	REAL LIFE EXPERIENCE OF HOME CARE ADMINISTRATION OF 5-AZACITIDINE AND DOMICILIARY MANAGEMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (submitted in 2019)
	4CPS-156	ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (submitted in 2019)
	4CPS-157	INTRAVENOUS BIOSIMILAR PRESCRIBING TRENDS IN A THIRD LEVEL SPANISH HOSPITAL (submitted in 2019)
	4CPS-158	PRESCRIBING TRENDS OF ADALIMUMAB AND ETANERCEPT BIOSIMILAR DRUGS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	4CPS-159	MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL (submitted in 2019)
	4CPS-160	MANAGEMENT OF DRUGS IN PATIENTS WITH SWALLOWING DIFFICULTIES IN A PUBLIC RESIDENTIAL CARE HOME: ROLE OF THE HOSPITAL PHARMACIST (submitted n 2019)
	4CPS-161	PHARMACIST INTERVENTIONS IN A HOSPITAL AT HOME UNIT (submitted in 2019)
	4CPS-162	PHARMACEUTICAL INTERVENTIONS IN DRUGS PROVIDED TO THE OUTPATIENT HOSPITAL PHARMACY (submitted in 2019)
	4CPS-163	CLINICAL PHARMACIST RESIDENCE IN AN INTENSIVE CARE UNIT: SCOPE AND RELEVANCE (submitted in 2019)
	4CPS-164	A SAFE HANDLING HAZARDOUS DRUGS STRATEGY TO IMPROVE THE SAFETY OF HEALTH PROFESSIONALS: REDUCING EXPOSURE BY MEDICAL PRESCRIPTION REVIEW IN NURSING HOMES (submitted in 2019)
	4CPS-165	ANALYSIS OF ANTIBIOTIC CONSUMPTION IN A NURSING HOME (submitted in 2019)
	4CPS-166	ANALYSIS OF THE MAINTENANCE RATE OF LONG ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT IN OUTPATIENTS (submitted in 2019)
	4CPS-167	EVALUATION OF PHARMACEUTICAL INTERVENTIONS: IMPROVEMENT PLANS (submitted in 2019)
	4CPS-168	DEVELOPMENT OF A BELGIAN CLASSIFICATION SYSTEM FOR CLINICAL PHARMACY ACTIVITIES (submitted in 2019)
	4CPS-169	EFFECT OF ABIRATERONE VERSUS ENZALUTAMIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (submitted in 2019)
	4CPS-170	ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL (submitted in 2019)
	4CPS-171	PHARMACISTS AT THE HEALTH CENTRE (submitted in 2019)
	4CPS-172	OFF-LABEL USE OF INTRALESIONAL CIDOFOVIR IN RECURRENT RESPIRATORY PAPILLOMATOSIS: A CASE REPORT. (submitted in 2019)
	4CPS-173	ROLE OF THE PHARMACIST IN THE MULTIDISCIPLINARY MANAGEMENT OF OSTEOMYELITIS: FROM MEDICATION RECONCILIATION TO SUPPORT IN CLINICAL DECISION MAKING. (submitted in 2019)
	4CPS-174	FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST (submitted in 2019)
	4CPS-175	EVOLUTION OF ANTIMICROBIAL CONSUMPTION IN A TRAUMA INTENSIVE CARE UNIT USING DEFINED DAILY DOSES PER 100 OCCUPIED BED DAYS (submitted in 2019)
	4CPS-176	ELECTROLYTE DISTURBANCES IN PREMATURE INFANTS WITH INTRAUTERINE GROWTH RESTRICTION RECEIVING PARENTERAL NUTRITION (submitted in 2019)
	4CPS-177	COMPARATIVE STUDY OF PATIENT PROFILES AND INITIAL ANTIRETROVIRAL TREATMENT IN 2014 VERSUS 2018 (submitted in 2019)
	4CPS-178	TRANSCRIPTION OF SUPPORTIVE MEDICATION FOR INPATIENT CHEMOTHERAPY BY DESIGNATED ONCOLOGY WARD PHARMACISTS (submitted in 2019)
	4CPS-179	THE WIDE REVIEW OF POLYPHARMACY IN THE FRAIL OLDER PERSON (submitted in 2019)
	4CPS-180	FROM EVIDENCE BASED MEDICINE TO PRACTICE: GUM CHEWING FOR POSTOPERATIVE RECOVERY OF GASTROINTESTINAL FUNCTION AFTER COLORECTAL SURGERY WITH INTERPROFESSIONAL TEAMWORK (submitted in 2019)
	4CPS-181	BUDGETARY IMPACT OF BIOSIMILAR PRESCRIPTION IN THE TREATMENT OF RHEUMATIC DISEASES (submitted in 2019)
	4CPS-182	PRELIMINARY DESIGN OF HOSPITAL TELEPHARMACY (submitted in 2019)
	4CPS-183	SELECTION OF A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SUITABLE FOR THERAPEUTIC DRUG MONITORING (submitted in 2019)
	4CPS-184	EVALUATION OF A CLINICAL PHARMACY SERVUCE ON AN INPATIENT WARD IN AN ACUTE HOSPITAL (submitted in 2019)
	4CPS-185	ADMINISTRATION OF ORAL ANTICANCER DRUGS FOR PATIENTS WITH SWALLOWING DIFFICULTIES (submitted in 2019)
	4CPS-186	DESCRIPTION OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT (submitted in 2019)
	4CPS-187	PROGNOSTIC VALUE OF HAEMATOLOGICAL INFLAMMATORY MARKERS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH PEMBROLIZUMAB (submitted in 2019)
	4CPS-188	PHARMACEUTICAL INTERVENTION TO REDUCE THE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS (submitted in 2019)
	4CPS-189	FALL INCIDENTS IN NURSING HOME PATIENTS: DEVELOPMENT OF A PREDICTIVE CLINICAL RULE (FINDER) (submitted in 2019)
	4CPS-190	EVALUATION OF A NEW CLINICAL PHARMACY SERVICE WITHIN A NEWLY LAUNCHED SURGICAL ADMISSION PROCESS (submitted in 2019)
	4CPS-191	PHARMACEUTICAL INTERVENTIONS IN A MEDICATION RECONCILIATION PROGRAMME UPON ADMISSION IN SURGICAL PATIENTS (submitted in 2019)
	4CPS-192	ESTIMATING THE SURVIVAL PROGNOSIS OF PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCY ON HOME PARENTERAL NUTRITION: A RETROSPECTIVE, MONOCENTRE STUDY (submitted in 2019)
	4CPS-193	MEASURING THE IMPACT OF HOSPITAL PHARMACIST PRESCRITION REVIEWING IN AN ONCOLOGY SETTING ON THE PHARMACOVIGILANCE REPORTING IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019)
	4CPS-194	THE UNDERREPORTING RATE AS A PHARMACOVIGILANCE PROCESS INDICATOR IN A COMPREHENSIVE CANCER CENTRE (submitted in 2019)
	4CPS-195	PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION FOR CRITICALLY ILL PATIENTS (submitted in 2019)
	4CPS-196	STABILITY OF LIPID EMULSION IN PAEDIATRIC PARENTERAL NUTRITION WITH HIGH ELECTROLYTIC LOAD (submitted in 2019)
	4CPS-197	MONITORING OF OFF-LABEL USE: ANALYSIS OF PRESCRIPTIONS IN THE PHARMACY'S ANTIBLASTIC DRUGS UNIT (submitted in 2019)
	4CPS-198	RESULTS OF A MEDICATION RECONCILIATION PROGRAMME IN COMPLEX CHRONIC PATIENTS AT HOSPITAL DISCHARGE (submitted in 2019)
	4CPS-199	PHARMACEUTICAL INTERVENTIONS IN HAEMODIALYSIS PATIENTS: A 2 YEAR OVERVIEW (submitted in 2019)
	4CPS-200	DIFFERENCES IN ALLELIC FREQUENCIES OF RELEVANT PHARMACOGENETIC POLYMORPHISMS MAY LEAD TO LOCAL GENE PANEL DEVELOPMENT (submitted in 2019)
	4CPS-201	IDENTIFICATION OF HAZARDOUS DRUGS AND PROCESS IN A UNIVERSITY HOSPITAL (submitted in 2019)
	4CPS-202	NUTRITIONAL RISK EVALUATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A PUBLIC NURSING HOME (submitted in 2019)
	4CPS-203	NURSES: WHAT DO YOU THINK ABOUT A PHARMACEUTICAL PRESENCE IN THE EMERGENCY WARD? (submitted in 2019)
	4CPS-204	MEDICINE RECONCILIATION AT HOSPITAL DISCHARGE (submitted in 2019)
	4CPS-205	ASSESSMENT OF THE PALATABILITY OF ANTIBIOTIC ORAL SUSPENSIONS: A LITERATURE REVIEW. (submitted in 2019)
	4CPS-206	IMPACT OF MEDICATION RECONCILIATION IN COMPLEX CHRONIC PATIENTS (submitted in 2019)
	4CPS-207	TREATMENT ADEQUACY IN DOMICILIARY CARE PROGRAMME PATIENTS (submitted in 2019)
	4CPS-208	NUTRITIONAL SUPPORT IN ONCOLOGY: A CROSS SECTIONAL STUDY AMONG CANCER PATIENTS (submitted in 2019)
	4CPS-209	AN EXPLORATION INTO A PHARMACIST-LED MEDICINES RECONCILIATION SERVICE IN AN ACUTE HOSPITAL SETTING. (submitted in 2019)
	4CPS-210	PHARMACISTS’ COMMUNICATION WITH FOREIGN LANGUAGE SPEAKING PATIENTS IN A FOREIGNER SETTLEMENT AREA, JAPAN (submitted in 2019)
	4CPS-211	ADHERENCE AND INTERACTIONS IN PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE (submitted in 2019)
	4CPS-212	HEALTHCARE PROVIDERS' VIEWS OF PHARMACY TEAM INVOLVEMENT IN THE PREPARATION AND ADMINISTRATION OF MEDICINES ON INPATIENTS WARDS: AN EXPLORATORY STUDY (submitted in 2019)
	4CPS-213	PATIENT PERCEPTIONS OF GENERIC MEDICINES 20 YEARS AFTER THE RIGHT OF SUBSTITUTION BY PHARMACISTS (submitted in 2019)
	4CPS-214	IMPROVING INTRAVENOUS TO ORAL SWITCH BY IDENTIFYING AND TACKLING BARRIERS PERCEIVED BY PHYSICIANS AND NURSES (submitted in 2019)
	4CPS-215	THE IMPACT OF CLINICAL PHARMACIST DRIVEN INTERVENTIONS ON PATIENT SAFETY IN HOSPITALISED PATIENTS: PRELIMINARY RESULTS OF A POINT PREVALENCE STUDY (submitted in 2019)
	4CPS-216	PROMOTION OF THE QUALITY OF DRUG EDUCATION FOR THE PATIENTS USING NASOGASTRIC TUBE FEEDING BEFORE DISCHARGE (submitted in 2019)
	4CPS-217	NETUPITANT-PALONOSETRON IN BREAST CANCER: POTENTIAL DRUGS INTERACTIONS
	4CPS-218	ANTIDIABETIC TREATMENT IN FRAIL PATIENTS WITH TYPE II DIABETES ADMITTED TO THE EMERGENCY DEPARTMENT FOR ALTERED GLYCAEMIA
	4CPS-219	COMPARISON OF THE NUMBER OF PARENTAL NUTRITION PRESCRIPTIONS IN 2020 DURING THE COVID-19 PANDEMIC WITH THE SAME TIME PERIOD IN 2019
	4CPS-220	PATIENT SATISFACTION WITH PHARMACIST EDUCATION ON ORAL ANTICOAGULANT MEDICATION
	4CPS-221	EFFECT OF SARS-CoV-2 PANDEMIC ON DIRECT ORAL ANTICOAGULANTS USE IN THE PRIMARY CARE SETTING
	4CPS-222	CONCORDANCE BETWEEN GUIDELINES ON PERIOPERATIVE MANAGEMENT OF NOVEL ORAL ANTICOAGULANTS AND ITS IMPLEMENTATION AND PREVENTABLE CAUSES OF THE OCCURRENCE OF ISCHAEMIC STROKE
	4CPS-223	REAL WORLD EXPERIENCE OF SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION
	4CPS-224	THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS: ASSESSMENT OF THE CURRENT PRACTICES IN A 950 BED HOSPITAL GROUP
	4CPS-225	IMPLEMENTATION OF A COMPUTER ALGORITHM IN THE ELECTRONIC HEALTH RECORD TO IDENTIFY INPATIENTS WITH UNTREATED ATRIAL FIBRILLATION TO OPTIMISE STROKE PREVENTION
	4CPS-226	EFFECTIVENESS OF CARBOXYMALTOSE IRON IN PREOPERATIVE ANAEMIA TREATMENT
	4CPS-227	HUMAN SERUM ALBUMIN: ANALYSIS OF USE
	4CPS-228	VERNAKALANT VERSUS FLECAINIDE FOR CONVERSION OF RECENT ONSET ATRIAL FIBRILLATION IN PATIENTS ATTENDING THE EMERGENCY DEPARTMENT
	4CPS-229	ANALYSIS OF CLINICAL PHARMACIST INTERVENTIONS IN THE HEART FAILURE DAY HOSPITAL.
	4CPS-230	ANTIARRHYTHMIC THERAPY EVALUATION IN A HOSPITAL SETTING
	4CPS-231	REAL WORLD DATA OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF HYPERLIPIDAEMIA: ANALYSIS 3 YEARS AFTER INTRODUCTION IN CLINICAL PRACTICE
	4CPS-232	USE OF DUPILUMAB IN THE TREATMENT OF ATOPIC DERMATITIS IN REAL CLINICAL PRACTICE
	4CPS-233	HOME MANAGEMENT OF ACUTE MULTIPLE SCLEROSIS OUTBREAK: ADAPTATION TO CORONAVIRUS PANDEMIC
	4CPS-234	GLUCOCORTICOID INDUCED HYPERGLYCAEMIA IN NON-DIABETIC PATIENTS IN AN EMERGENCY DEPARTMENT
	4CPS-235	SYSTEMIC CORTICOSTEROIDS IN THE TREATMENT OF SARS-CoV-2 INFECTION
	4CPS-236	USE OF ETELCALCETIDE IN PATIENTS UNDERGOING HAEMODIALYSIS
	4CPS-237	FEASIBILITY OF CONTINUOUS ADMINISTRATION OF ANTIMICROBIALS IN HOSPITAL: NOTHING IS EVER AS IT SEEMS?
	4CPS-238	EVALUATION OF EFFECTIVENESS OF COMPOUNDED ORAL VANCOMYCIN CAPSULES FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
	4CPS-239	THERAPEUTIC DRUG MONITORING OF GENTAMICIN IN NEONATES
	4CPS-240	THERAPEUTIC MONITORING OF VANCOMYCIN IN A COHORT OF PAEDIATRIC PATIENTS
	4CPS-241	IMPACT OF ANTIBIOTIC PRESCRIBING IN AN EMERGENCY DEPARTMENT ON HOSPITAL STAYS, READMISSION AND MORTALITY
	4CPS-242	ACUTE RESPIRATORY INFECTIONS: AN ANALYSIS OF HOSPITAL ANTIBIOTHERAPY PRESCRIPTION QUALITY FOR THE PAEDIATRIC POPULATION
	4CPS-243	HEALHCARE ASSOCIATED CLOSTRIDIOIDES DIFFICILE INFECTION IN SURGICAL AND MEDICAL PATIENTS
	4CPS-244	THERAPEUTIC DRUG MONITORING GUIDED PHARMACY INTERVENTIONS TO OPTIMISE THE DOSAGE OF BETA-LACTAMS ADMINISTERED IN CONTINUOUS INFUSION IN NON-CRITICALLY ILL PATIENTS.
	4CPS-245	DURATION OF ANTIBIOTIC TREATMENT IN PATIENTS DISCHARGED FROM A SHORT STAY HOSPITALISATION UNIT
	4CPS-246	CORONAVIRUS FIRST WAVE EFFECT ON ANTIBIOTIC CONSUMPTION AND ANTIMICROBIAL RESISTANCE
	4CPS-247	VARIATIONS IN CONSUMPTION OF ANTIMICROBIALS IN INTERNAL MEDICINE WARDS OF HOSPITALS
	4CPS-248	APPROPRIATENESS OF THE CLOSTRIDIUM DIFFICILE INFECTION PRESCRIPTION PRIOR TO THE IMPLEMENTATION OF A PROTOCOL FOR ITS MANAGEMENT
	4CPS-249	SECOND GENERATION β-LACTAM/ β-LACTAMASE INHIBITOR COMBINATIONS: CEFTAZIDIME-AVIBACTAM AND CEFTOLOZANE-TAZOBACTAM EXPERIENCE OF USE
	4CPS-250	EVALUATION OF PRESCRIPTION ADEQUACY TO THE ANTIBIOTHERAPY PROTOCOL IN INTRA-ABDOMINAL INFECTION IN A REGIONAL HOSPITAL
	4CPS-251	EVALUATION OF CLOSTRIDIUM DIFFICILE INFECTION MANAGEMENT PRIOR TO IMPLEMENTATION OF A PROTOCOL FOR IMPROVEMENT
	4CPS-252	STUDY OF THE IMPLEMENTATION OF A VANCOMYCIN PHARMACOKINETIC MONITORING PROGRAMME IN PAEDIATRICS
	4CPS-253	THE IMPORTANCE OF THE PHARMACOKINETIC PROFILE IN PATIENTS WITH ULTRA-RARE DISEASES:A CASE REPORT
	4CPS-254	A RETROSPECTIVE STUDY OF ANTIMICROBIAL STEWARDSHIP IN A UNIVERSITY HOSPITAL
	4CPS-255	CLINICAL EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL
	4CPS-256	HEPATITIS C RETREATMENT OF A PATIENT WHO FAILED MULTIPLE TREATMENTS INCLUDING PROTEASE INHIBITOR AND NON-STRUCTURAL PROTEIN 5A INHIBITORS: A CASE REPORT
	4CPS-257	RELEVANCE OF RITONAVIR INTERACTIONS IN HIV TREATMENTS THAT INVOLVE TREATMENT MODIFICATION
	4CPS-258	EVALUATION OF MEDICINES ADHERENCE AND ASSOCIATED FACTORS IN PATIENTS WITH CHRONIC HEPATITIS B
	4CPS-259	ONE YEAR WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE
	4CPS-260	ANALYSIS OF DRUGS INTERACTIONS BETWEEN CORONAVIRUS (COVID-19) ANTIVIRAL TREATMENT AND CONCOMITANT MEDICATION
	4CPS-261	USE OF INTRAVENOUS IMMUNOGLOBULIN: BY THE BOOK?
	4CPS-262	CLINICAL EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN NEUROLOGY: A RETROSPECTIVE COHORT STUDY AT THE MATER MISERICORDIAE UNIVERSITY HOSPITAL
	4CPS-263	CASE REPORT OF KAWASAKI DISEASE AND SARS-COV-2 INFECTION IN A PAEDIATRIC HOSPITAL
	4CPS-264	AUTOIMMUNE MYOPATHY RESULTING FROM A THERAPY WITH NIVOLUMAB FOR METASTATIC NON-SMALL CELL LUNG CANCER: A CASE REPORT
	4CPS-265	CEMIPLIMAB FOR THE TREATMENT OF RELAPSE OF A CUTANEOUS SQUAMOUS CELL CARCINOMA IN AN ADULT PATIENT: A CASE REPORT
	4CPS-266	AFATINIB AS FIRSTLINE TREATMENT FOR ADVANCED LUNG ADENOCARCINOMA IN A PATIENT HARBOURING EXON 19 DELETION IN EGFR: A CASE REPORT
	4CPS-267	RETROSPECTIVE ANALYSIS OF CARBOPLATIN DOSING PRESCRIBED IN A CHEMOTHERAPY REGIMEN AND ITS RELATIONSHIP WITH TOXICITY
	4CPS-268	NIVOLUMAB VERSUS PEMBROLIZUMAB IN SECONDLINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE
	4CPS-269	HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ASSOCIATED WITH CYTOREDUCTIVE SURGERY IN PERITONEAL CANCER TREATMENTS: A MULTIDISCIPLINARY EXPERIENCE TO EVALUATE ITS EFFICACY
	4CPS-270	RESULTS OF EFFECTIVENESS AND SAFETY IN REAL CLINICAL PRACTICE OF NIVOLUMAB, PEMBROLIZUMAB AND ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER
	4CPS-271	EVALUATION OF THE EFFICACY OF ANTI-PD-L1 IMMUNOTHERAPY IN NON-MICROCRITICAL LUNG CANCER IN CLINICAL PRACTICE
	4CPS-272	PHARMACIST ROLE IN HEALTH OUTCOME OF VD-PACE SAVAGE REGIMEN IN AN ADULT FEMALE PATIENT WITH RARE RELAPSED AND REFRACTORY IgD LAMBDA MULTIPLE MYELOMA
	4CPS-273	DOES AGE REALLY MATTERS ON THE PREVALENCE OF DRUG-DRUG INTERACTIONS WITH ENDOVENOUS CHEMOTHERAPY?
	4CPS-274	REAL WORLD EFFECTIVENESS OF PALBOCICLIB AND RIBOCICLIB IN WOMEN WITH METASTATIC BREAST CANCER.
	4CPS-275	EFFICACY AND SAFETY OF TRIFLURIDINE/TIPIRACIL IN PATIENTS WITH METASTATIC COLORECTAL CANCER: REAL WORLD DATA
	4CPS-276	ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY REAL WORLD DATA STUDY.
	4CPS-277	CETUXIMAB VERSUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A COMPARATIVE EFFECTIVENESS AND PATIENT REPORTED OUTCOMES MULTI-COHORT STUDY
	4CPS-278	EFFECTIVENESS AND SAFETY OF CISPLATIN PLUS GEMCITABINE IN METASTATIC BREAST CANCER
	4CPS-279	CANCER PAIN MANAGEMENT APPROACH CONSIDERING POTENTIAL DRUG INTERACTIONS IN PATIENTS RECEIVING ORAL ANTITUMOUR TREATMENT
	4CPS-280	BENEFITS OF PHARMACOKINETIC ESTIMATION OF METHOTREXATE LEVELS IN PAEDIATRIC OSTEOSARCOMA PATIENTS
	4CPS-281	HIGH DOSE METHOTREXATE IN PEDIATRIC OSTEOSARCOMA PATIENTS: EFFECTIVENESS AND SAFETY.
	4CPS-282	EPIDEMIOLOGY AND CLINICAL COURSE OF PATIENTS WITH CANCER DIAGNOSED WITH SARS-COV-2 INFECTION
	4CPS-283	ONCOHAEMATOLOGICAL PHARMACEUTICAL CARE CONSULTATION. IS THE INFORMATION ON THE EUROPEAN PUBLIC ASSESSMENT REPORT OF DRUGS ENOUGH?
	4CPS-284	TREATMENT OF CYCLIN INHIBITOR INDUCED NEUTROPENIA: IMPACT ON PROGRESSION FREE SURVIVAL
	4CPS-285	MULTIDISCIPLINARY ORAL THERAPY OUTPATIENT CLINIC: AN ITALIAN SINGLE CENTRE EXPERIENCE
	4CPS-286	EARLY IMPACT OF COVID ON THE ACTIVITY OF A CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT AT A TERTIARY CARE HOSPITAL
	4CPS-287	IMPACT OF SARS-COV-2 INFECTION IN ACUTE MYELOID LEUKAEMIA PATIENTS: EXPERIENCE OF THE PETHEMA REGISTRY
	4CPS-288	CLINICAL PHARMACIST'S IMPACT IN IMPROVING THE SAFETY OF THERAPIES FOR PATIENTS USING ORAL ANTICANCER AGENTS: A PROSPECTIVE SINGLE CENTRE STUDY
	4CPS-289	ANALYSIS OF ANTINEOPLASTIC DRUG CONTAMINATION LEVEL IN THE HOSPITAL PHARMACY: PROBLEM MONITORING AND SOLVING
	4CPS-290	BORTEZOMIB INDUCED ACUTE NECROHAEMORRHAGIC PANCREATITIS: A CASE REPORT
	4CPS-291	PALBOCICLIB: EARLY NEUTROPENIA AS A PHARMACODYNAMIC MARKER IN A REAL WORLD SETTING?
	4CPS-292	EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHATIC LEUKAEMIA: MULTICENTRE STUDY
	4CPS-293	EFFICACY AND SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER
	4CPS-294	EFFICACY AND SAFETY PROFILE OF TRIFLURIDINE TIPIRACIL AND REGORAFENIB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER
	4CPS-295	IMMUNOTHERAPY FOR CANCER THERAPEUTIC POSITIONING REPORTS: KNOWLEDGE, EXPECTATIONS AND EXPERIENCES THROUGH A NATIONAL SURVEY.
	4CPS-296	IMPACT OF THE COVID-19 PANDEMIC ON CLINICAL LUNG CANCER MANAGEMENT
	4CPS-297	SPINAL CORD APLASIA CAUSED BY 6-MERCAPTOPURINE IN A CAUCASIAN GIRL WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND HOMOZYGOUS MUTATION IN NUDIX HYDROLASE 15: CASE REPORT
	4CPS-298	EFFICACY AND SAFETY PROFILE OF ANTI-EGFR TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
	4CPS-299	PATIENTS’ MISCONCEPTIONS FOLLOWING INITIATION OF ANTINEOPLASTIC TREATMENT FOR COLORECTAL CANCER
	4CPS-300	EFFECTIVENESS AND SAFETY OF CEMIPLIMAB IN SQUAMOUS CELL CARCINOMA OF THE SKIN IN A THIRD LEVEL HOSPITAL
	4CPS-301	ASSOCIATION OF ANTIBIOTICS AND PROTON PUMP INHIBITORS ON CLINICAL ACTIVITY OF FIRSTLINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER: 2 YEARS OF REAL WORLD DATA
	4CPS-302	SORAFENIB IN HEPATOCARCINOMA: RESULTS IN A REAL WORLD SETTING
	4CPS-303	EFFICACY AND SAFETY OF MONOTHERAPY WITH PEMBROLIZUMAB IN NON-MICROCYTIC METASTATIC LUNG CANCER IN CLINICAL PRACTICE.
	4CPS-304	RITUXIMAB AS AN ALTERNATIVE IN NEUROLOGIC DISORDERS: LONG TERM STUDY
	4CPS-305	EFFECTIVENESS AND SAFETY OF BRAF/MEK INHIBITORS IN ADVANCED OR METASTATIC MELANOMA IN TWO TERTIARY HOSPITALS
	4CPS-306	DAROLUTAMIDE, ENZALUTAMIDE AND APALUTAMIDE: PLACE IN THERAPEUTICS OF CASTRATION RESISTANT NON METASTATIC PROSTATE CANCER
	4CPS-307	SAFETY EVALUATION OF NEW ANTIANDROGENIC DRUGS IN CASTRATION RESISTANT NON-METASTATIC PROSTATE CANCER
	4CPS-308	EXPERIENCE WITH TERIFLUNOMIDE TREATMENT FOR MULTIPLE SCLEROSIS IN A UNIVERSITY HOSPITAL
	4CPS-309	BARRIERS TO ADHERENCE WITH PRESCRIBED TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS
	4CPS-310	TOFACITINIB EFFECTIVENESS AND SAFETY RESULTS: REAL WORLD DATA
	4CPS-311	REAL WORLD TOXICITY AND MANAGEMENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPIES TARGETING CD19 IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
	4CPS-312	PHARMACEUTICAL INTERVENTIONS IN A NON-ONCOHAEMATOLOGICAL DAILY HOSPITAL
	4CPS-313	EXPERIENCE OF THE USE OF BARICITINIB IN COVID-19 PNEUMONIA
	4CPS-314	3 DAY COURSE OF LOW DOSE SUBCUTANEOUS ANAKINRA IN PATIENTS WITH REFRACTORY MODERATE-SEVERE COVID-19: A PROOF-OF-CONCEPT STUDY
	4CPS-315	EVALUATION OF THE EFFECTIVENESS OF EARLY ADMINISTRATION OF TOCILIZUMAB IN PATIENTS WITH COVID-19
	4CPS-316	MULTIPLE SCLEROSIS OUTPATIENT PHARMACEUTICAL CARE BY AN IMPLANTED TELEPHARMACY TOOL DURING SARS-COV-2 PANDEMIC
	4CPS-317	IMMUNOSUPPRESSIVE TREATMENT MANAGEMENT IN A COHORT OF HOSPITALIZED SOLID ORGAN RECIPIENTS AFFECTED BY COVID-19
	4CPS-318	COMPOUNDING TACROLIMUS OPHTHALMIC OINTMENT 0,02% IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE OPHTHALMIC SYNDROMES: EFFECTIVENESS AND SAFETY ASSESSMENT
	4CPS-319	PIRFENIDONE AND NINTEDANIB FOR THE TREATMENT OF THE IDIOPATHIC PULMONARY FIBROSIS: AN ITALIAN HOSPITAL EXPERIENCE
	4CPS-320	IMPROVING MEDICATION ADHERENCE AND PATIENTS’ EXPERIENCE AFTER HEART TRANSPLANT USING A MULTILEVEL eHEALTH INTERVENTION: THE mHEART CLINICAL TRIAL
	4CPS-321	ANAKINRA IN SEVERE COVID-19 PNEUMONIA: RETROSPECTIVE STUDY
	4CPS-322	ADALIMUMAB CONCENTRATIONS PRIOR TO THE IMPLEMENTATION OF THERAPEUTIC DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
	4CPS-323	EVALUATION OF THE USE, ADHERENCE AND TOLERANCE OF 0.03% TACROLIMUS EYE DROPS
	4CPS-324	EFFECTIVENESS AND SAFETY OF IXEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
	4CPS-325	EFFECTS ON ADHERENCE IN PATIENTS WITH ARTHROPATHIES CHANGING TREATMENT
	4CPS-326	ADALIMUMAB’S PERSISTENCE IN RHEUMATHOLOGICAL DISEASES
	4CPS-327	EFFECTIVENESS, SAFETY AND ADHERENCE OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS
	4CPS-328	BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS ACCORDING TO THE MECHANISM OF ACTION
	4CPS-329	DO PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES THINK THEY KNOW THEIR MEDICATION?
	4CPS-330	INDIVIDUALISING THERAPIES THROUGH PHARMACOKINETICS: ADALIMUMAB FOR INFLAMMATORY BOWEL DISEASE
	4CPS-331	MMATORY PARAMETERS ANALYSIS IN SEVERE COVID-19 PATIENTS TREATED WITH TOCILIZUMAB
	4CPS-332	TOCILIZUMAB FOR TREATING COVID PNEUMONIA: ANALYSIS OF EFFECTIVENESS AND SECURITY
	4CPS-333	TREATING MULTIPLE SCLEROSIS PATIENTS WITH INFUSION OF DISEASE MODIFYING TREATMENTS DRUGS DURING THE COVID-19 PANDEMIC
	4CPS-334	INFLUENCE OF ANTHROPOMETRIC, DEMOGRAPHIC AND THERAPEUTIC FACTORS ON SERUM CONCENTRATIONS OF ANTI-TNF DRUGS
	4CPS-335	EXPERIENCE IN THE USE OF TOCILIZUMAB IN PATIENTS WITH COVID-19. HAS IT REALLY BEEN EFFECTIVE?
	4CPS-336	IMPACT OF CHECK OF MEDICATION APPROPRIATENESS (CMA) IN OPTIMISING ANALGESIC PRESCRIBING
	4CPS-337	PERSISTENCE OF BIOSIMILAR TREATMENT FOR IMMUNE MEDIATED INFLAMMATORY DISEASES IN CLINICAL PRACTICE
	4CPS-338	USE AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
	4CPS-339	INTRATHECAL ADMINISTRATION OF BACLOFEN FOR THE REDUCTION OF SPASTICITY
	4CPS-340	PROFILE OF PATIENTS WITH ABUSIVE CONSUMPTION OF QUICK RELEASE FENTANYL IN A HEALTHCARE AREA
	4CPS-341	THE ROLE OF PHARMACISTS IN PROVIDING PHARMACEUTICAL CARE FOR PATIENTS WITH HEADACHES
	4CPS-342	TRANSIENT VALPROIC ACID TOXICITY: HYPERAMMONAEMIA IN A PAEDIATRIC PATIENT
	4CPS-343	PREGABALIN AND GABAPENTIN DRUG UTILISATION REVIEW
	4CPS-344	PRESCRIPTION AUDITING OF THE 3 MONTHLY FORMULATION OF PALIPERIDONE PALMITATE IN ADULT PATIENTS WITH SCHIZOPHRENIA
	4CPS-345	MANAGEMENT OF BRONCHIOLITIS IN HOSPITALISED CHILDREN
	4CPS-346	EVALUATION OF THE IMPLEMENTATION OF "INHALER INTERVIEWS" DURING MEDICATION RECONCILIATION IN THE PNEUMOLOGY SERVICE
	4CPS-347	CLINICAL TRIAL DRUGS: DISPENSING OPTIMISATION FOR OUTPATIENTS OF A CANCER CENTRE
	4CPS-348	THE HOSPITAL PHARMACY IN THE CREATION OF CLEAN CIRCUITS IN THE FACE OF COVID-19
	4CPS-349	ROLE OF HOSPITAL PHARMACISTS IN ONCOGERIATRIC CONSULTATIONS: A RETROSPECTIVE STUDY
	4CPS-350	ROLE OF THE PHARMACIST IN INTERNAL MEDICINE: ANALYSIS OF PHARMACEUTICAL INTERVENTIONS DURING A ROTATION IN AN INTERNAL MEDICINE DEPARTMENT
	4CPS-351	MEDICATION DELIVERY CONFIRMATION TO AMBULATORY PATIENTS BY INSTANT MESSAGING APP
	4CPS-352	PATIENTS IN CHARGE: WHY WE SHOULD IMPLEMENT AN ONLINE PERSONAL HEALTH RECORD AS A TOOL FOR MEDICATION RECONCILIATION
	4CPS-353	COLLABORATION BETWEEN HOSPITAL AND COMMUNITY PHARMACISTS ABOUT DISCHARGED PATIENTS: A PILOT STUDY
	4CPS-354	EFFICACY AND SAFETY WITH ERENUMAB AND GALCANEZUMAB: OUR EXPERIENCE
	4CPS-355	EVALUATION OF PATIENTS CONSULTING THE EMERGENCY DEPARTMENT FOR BRADYCARDIA RELATED TO MEDICATION
	4CPS-356	COST-MINIMISATION ANALYSIS OF THE USE OF NIVOLUMAB AND PEMBROLIZUMAB
	4CPS-357	CLINICAL CHARACTERISTICS AND MORTALITY OF COVID-19 IN A LONG TERM CARE FACILITY
	4CPS-358	POINT PREVALENCE REVIEW OF MEDICINES RECONCILIATION FOLLOW-UP BY MEDICAL TEAMS
	4CPS-359	DEVELOPMENT AND VALIDATION OF A 30 DAY REVISIT RISK PREDICTION MODEL IN PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT DUE TO DRUG RELATED PROBLEMS
	4CPS-360	RISK OF MALNUTRITION IN PATIENTS WITH COVID-19 DISEASE WHO RECEIVE ORAL NUTRITIONAL SUPPLEMENTS
	4CPS-361	INTERVENTIONS OF A CLINICAL PHARMACIST IN AN INTENSIVE CARE UNIT
	4CPS-362	NONAGENARIANS VERSUS NON-NONAGENARIANS IN THE HIP FRACTURE PATIENT: FROM A PHARMACOTHERAPEUTIC POINT OF VIEW
	4CPS-363	DOES PATIENT CENTRED CARE PRACTICE IMPROVE MEDICATION ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES MELLITUS?
	4CPS-364	PERSONALISED QT RISK ASSESSMENT - TO INFORM MEDICATION PRESCRIBING?
	4CPS-365	INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY COMPLEX CHRONIC PATIENT CARE TEAM
	4CPS-366	COMPARING THE MEDICATION PROCESS ACROSS COUNTRIES USING THE FUNCTIONAL RESONANCE ANALYSIS METHOD
	4CPS-367	IMPACT OF PHARMACEUTICAL CONSULTATION IMPLEMENTATION ON THE PHARMACEUTICAL INTERVENTIONS AND THE ROLE OF PHARMACISTS IN MULTIDISCIPLINARY TEAMS
	4CPS-368	SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN ANTICHOLINERGIC BURDEN AND XEROSTOMIA AND XEROPHTHALMIA
	4CPS-369	PHARMACHECK AS A SCREENING TOOL TO INTERCEPT HIGH RISK SITUATIONS IN INTERNAL MEDICINE THAT COULD LEAD TO ADVERSE DRUG EVENTS
	4CPS-370	PHARMACISTS´ INTERVENTIONS BEFORE AND AFTER THE USE OF A CLINICAL DECISION SUPPORT TOOL TO DETECT DRUG RELATED PROBLEMS
	4CPS-371	USABILITY EVALUATION OF A PERSONALISED HEALTH RECORD FOR DETECTING MEDICATION DISCREPANCIES
	4CPS-372	PHARMACEUTICAL INTERVENTIONS IN HOSPITALIZED PATIENTS DURING THE FIRST WAVE OF SARS-COV-2 PANDEMIC
	4CPS-373	PHARMACEUTICAL CARE IN HOSPITALISATION UNITS: ANALYSIS OF INTERVENTIONS
	4CPS-374	A SCREENING MODEL TO IDENTIFY ELDERLY POLYPHARMACY PATIENTS THAT MAY BENEFIT FROM PHARMACIST LED MEDICATION REVIEW DURING HOSPITAL ADMISSION
	4CPS-375	EXCESSIVE POLYPHARMACY AND OTHER DETERMINANTS FOR UNPLANNED HOSPITAL ADMISSIONS
	4CPS-376	ANTIRETROVIRAL THERAPY OPTIMISATION STRATEGIES IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS: A DECISIVE TASK FOR HOSPITAL PHARMACISTS
	4CPS-377	APPROPRIATENESS OF NUTRITIONAL SUPPORT FOR PATIENTS WITH INVASIVE MECHANICAL VENTILATION WITH COVID-19 DISEASE REQUIRING INTENSIVE CARE
	4CPS-378	ORAL THERAPY ADHERENCE AND SATISFACTION IN PATIENTS WITH MULTIPLE MYELOMA
	4CPS-379	PARENTERAL NUTRITION MANAGEMENT IN CORONAVIRUS CRITICAL PATIENTS: CASE REPORT
	4CPS-380	AN INTEGRATED PHARMACIST LED MEDICATION REVIEW SERVICE FOR ELECTIVE SURGERY PATIENTS AT THE PRE-ANAESTHESIA OUTPATIENT CLINIC
	4CPS-381	PROACTIVE MEDICATION RECONCILIATION AND PATIENT FLOW IN THE EMERGENCY DEPARTMENT ADMISSIONS
	4CPS-382	IMPACT OF A CLINICAL PHARMACIST AT TRANSITION OF CARE: A PROSPECTIVE STUDY IN AN ORTHOPAEDIC WARD OF A REGIONAL HOSPITAL
	4CPS-383	DRUG PRESCRIPTION IN THE ELDERLY. ARE WE DOING WELL?
	4CPS-384	POTENTIAL DRUG-RELATED PROBLEMS IN THE TIME OF COVID-19
	4CPS-385	IMPACT OF FULLY AUTOMATISED CENTRAL INTRAVENOUS ADDITIVE SERVICE (CIVAS) ON DAILY NURSING PRACTICE
	4CPS-386	ONE YEAR EXPERIENCE OF A NEW PROGRAMME OF TELEMATIC PHARMACEUTICAL CONSULTATION AND DELIVERY OF HOSPITAL DISPENSING MEDICATION
	4CPS-387	COVID-19 TREATMENT: A FOLLOW-UP OF INPATIENTS DURING THE SECOND WAVE OF THE PANDEMIC
	4CPS-388	TELEPHARMACY DURING SARS-COV-2
	4CPS-389	GOVERNANCE OF CLINICAL TRIALS BETWEEN HEALTH NEEDS, ACCESS TO CARE, INNOVATION AND SUSTAINABILITY IN THE COVID-19 PANDEMIC ERA
	4CPS-390	DISPENSING OF ANTICANCER INVESTIGATIONAL DRUGS DURING THE LOCKDOWN FOR THE SARS-COV-2 PANDEMIC: EXPERIENCE IN AN ONCOLOGICAL CENTRE
	4CPS-391	NON-ADHERENCE IN RHEUMATOLOGICAL IMMUNE MEDIATED DISEASES
	4CPS-392	EFFECT OF COVID 19 PANDEMIC ON ANTIRETROVIRAL THERAPY ADHERENCE
	4CPS-393	IMPACT OF MULTIDISCIPLINARY TEAM INTERVENTION IN MEDICATION RECONCILIATION FOR GERIATRIC PATIENTS
	4CPS-394	EVALUATION OF THE DEGREE OF THERAPEUTIC KNOWLEDGE IN LUNG TRANSPLANT RECIPIENTS
	4CPS-395	PHARMACY SERVICE’S ADAPTATION TO THE COVID-19 PANDEMIC: TELEPHARMACY AND HOME DRUG DELIVERY
	4CPS-396	EFFECT OF PATIENT'S OWN MEDICATION USE ON PATIENT SELF-REPORTED MEDICATION KNOWLEDGE DURING HOSPITALISATION: A PRE-POST INTERVENTION STUDY
	4CPS-397	ASSESSMENT OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT AFTER COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEM IMPLEMENTATION
	4CPS-398	USE OF INTRAVENOUS IRON IN HEART FAILURE OCTOGENARIANS AND NONAGENARIANS WITH IRON DEFICIENCY
	4CPS-399	EVALUATING CLINICAL PHARMACY SERVICES ON AN INTENSIVE CARE UNIT: A SATISFACTION SURVEY
	4CPS-400	THE ROLE AND VALUE OF A WARD BASED PHARMACIST IN THE INTENSIVE CARE UNIT: THE CRITICAL CARE PHYSICIANS’ AND NURSES’ PERCEPTIONS
	4CPS-401	TELEPHARMACY PROGRAMME IMPLEMENTATION DURING THE COVID-19 PANDEMIC
	4CPS-402	COVID-19 AND DIGESTIVE SURGERY: MEDICAL DEVICES FOR SURGICAL SMOKE FILTRATION
	4CPS-403	CHRONIC KIDNEY DISEASE (CKD) PATIENTS AND POLYPHARMACY: HOW TO OPTIMISE AND SIMPLIFY PRESCRIPTIONS?
	4CPS-404	MULTIDISCIPLINARY TEAM AIMED TO OPTIMISE INDIVIDUALISED SPECIAL DRUGS PRESCRIPTIONS AND AUTHORISATION BY HOSPITAL MEDICAL DIRECTOR THROUGH AN INFORMATIC APPLICATION
	4CPS-405	STRONGYLOIDES STERCORALIS PROPHYLAXIS WITH IVERMECTIN IN COVID-19 PATIENTS

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-001	PHARMACIST INTERVENTION TO IMPROVE THE SAFETY OF PATIENTS TREATED WITH PROTON PUMP INHIBITORS (submitted in 2019)
	5PSQ-002	HYPOMAGNESAEMIA ALERT! MONITOR CLOSELY THE PROTON PUMP INHIBITORS FOR CHRONIC TREATMENT IN ELDERLY PATIENTS (submitted in 2019)
	5PSQ-003	EFFECTIVENESS OF ANTIEMETIC THERAPY DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL (submitted in 2019)
	5PSQ-004	ADEQUACY OF ANTIEMETIC TREATMENT DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL (submitted in 2019)
	5PSQ-005	ANALYSIS OF THE ADEQUACY OF VITAMIN D PRESCRIPTIONS (submitted in 2019)
	5PSQ-006	PARENTERAL NUTRITION IN A NEONATOLOGY INTENSIVE CARE UNIT: DURATION AND COMPLICATIONS (submitted in 2019)
	5PSQ-007	THE PHARMACEUTICAL GOVERNANCE OF LOW MOLECULAR WEIGHT HEPARINS: APPROPRIATENESS ANALYSIS (submitted in 2019)
	5PSQ-008	RESISTANCE TO SODIUM HEPARIN TREATMENT OR TREATMENT FAILURE TO THE EQUIVALENT ANALOGUE? (submitted in 2019)
	5PSQ-009	EVALUATION OF DIRECT ORAL ANTICOAGULANT USE IN PATIENTS ADMITTED FOR UPPER GASTROINTESTINAL AND INTRACRANIAL HAEMORRHAGES IN THE EMERGENCY SERVICE (submitted in 2019)
	5PSQ-010	BENEFITS PROVIDED BY RECOMBINANT LONG HALF-LIFE COAGULATION FACTORS IN PATIENTS WITH SEVERE HAEMOPHILIA “A” IN PROPHYLAXIS (submitted in 2019)
	5PSQ-011	COMPLICATIONS OF DRUG CONTAINING PARENTERAL NUTRITION: A COHORT STUDY. (submitted in 2019)
	5PSQ-012	DRUG INTERACTIONS AND POLYPHARMACY IN A COHORT OF HIV POSITIVE HAEMOPHILIAC PATIENTS (submitted in 2019)
	5PSQ-013	ANALYSIS OF THE RISK OF QT INTERVAL PROLONGATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A NURSING HOME (submitted in 2019)
	5PSQ-014	RETROSPECTIVE EVALUATION OF RESUSCITATION MEDICATION UTILISATION IN HOSPITALISED ADULT PATIENTS WITH CARDIAC ARREST (submitted in 2019)
	5PSQ-015	COMPARING THREE CRITERIA FOR ASSESSMENT OF WHAT MEDICINES INCLUDED IN NATIONAL HOSPITAL FORMULARY ARE CLASSIFIED AS POTENTIALLY INAPPROPRIATE MEDICATIONS FOR OLDER PATIENTS (submitted in 2019)
	5PSQ-016	TOLVAPTAN ASSOCIATED CREATINE KINASE ELEVATION IN TWO PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (submitted in 2019)
	5PSQ-017	PCSK-9 INHIBITORS: REAL WORLD EFFECTIVENESS (submitted in 2019)
	5PSQ-018	ADALIMUMAB IN PALMOPLANTAR PUSTULOSIS (submitted in 2019)
	5PSQ-019	EFFICACY OF SECUKINUMAB IN MODERATE-SEVERE PSORIASIS WITH A REDUCED TREATMENT REGIMEN (submitted in 2019)
	5PSQ-020	ANALYSIS OF THE EFFECTIVENESS OF SECUKINUMAB AND IXEKIZUMAB IN THE TREATMENT OF MODERATE-SEVERE PSORIASIS (submitted in 2019)
	5PSQ-021	TRANSVAGINAL MESH IN PELVIC ORGAN PROLAPSES: 2017-2019 RETROSPECTIVE ANALYSIS (submitted in 2019)
	5PSQ-022	ANALYSIS OF INFECTIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS USED FOR ADMINISTRATION OF PARENTERAL NUTRITION IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	5PSQ-023	EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM IN INFECTIONS BY MULTIRESISTANT MICROORGANISMS. (submitted in 2019)
	5PSQ-024	PHARMACOLOGIC INTERVENTION BY HOSPITAL PHARMCIST FOR LEUCOPENIA DUE TO TAZOBACTAM/PIPERACILLIN IN THE POSTPARTUM PERIOD: A CASE REPORT (submitted in 2019)
	5PSQ-025	PHARMACEUTICAL INTERVENTION FOR THE OPTIMISATION THE USE OF ANTIBIOTICS IN A TERTIARY HOSPITAL (submitted in 2019)
	5PSQ-026	IMPACT OF THE EARLY SWITCHING FROM INTRAVENOUS TO ORAL ANTIBIOTICS IN A TERTIARY HOSPITAL (submitted in 2019)
	5PSQ-027	OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY WORKING GROUP IN A HOSPITAL AT HOME UNIT: THE ESSENTIAL ROLE OF PHARMACISTS (submitted in 2019)
	5PSQ-028	PRESCRIPTION PROFILE OF ISAVUCONAZOLE IN THE REAL WORLD CLINICAL PRACTICE (submitted in 2019)
	5PSQ-029	SAFE ADMINISTRATION OF SOFOSBUVIR/VELPATASVIR IN A PATIENT WITH PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (submitted in 2019)
	5PSQ-030	ADVERSE DRUG REACTIONS DUE TO INTERACTION WITH COBICISTAT OR RITONAVIR IN HIV POSITIVE PATIENTS: A CASE SERIES (submitted in 2019)
	5PSQ-031	CLINICAL AND ECONOMIC IMPACT AFTER BREAKING THE SINGLE TABLET ABACAVIR/LAMIVUDINE/DOLUTEGRAVIR COMBO TREATMENT INTO TWO DRUG REGIMENES (submitted in 2019)
	5PSQ-032	SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C INFECTION WITH CRUSHED SOFOSBUVIR/VELPATASVIR (submitted in 2019)
	5PSQ-033	GLECAPREVIR/PIBRENTASVIR USE IN CHRONIC HEPATITIS C: EFFECTIVENESS AND SAFETY (submitted in 2019)
	5PSQ-034	EVALUATION OF OSELTAMIVIR USE IN CLINICAL PRACTICE IN A SECOND LEVEL HOSPITAL. (submitted in 2019)
	5PSQ-035	DUAL THERAPY WITH DOLUTEGRAVIR AND LAMIVUDINE: EFFICACY AND SAFETY. (submitted in 2019)
	5PSQ-036	STOPP/START CRITERIA IN PATIENTS WITH HIV (submitted in 2019)
	5PSQ-037	DOCETAXEL INDUCED NEUTROPENIC ENTEROCOLITIS: A CASE REPORT (submitted in 2019)
	5PSQ-038	SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF BREAST CANCER WITH POSITIVE HORMONAL RECEPTORS AND NEGATIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2. (submitted in 2019)
	5PSQ-039	PANCREATITIS INDUCED BY IMMUNOTHERAPY? TWO CASE REPORTS (submitted in 2019)
	5PSQ-040	SECURITY PROFILE OF IBRUTINIB AS MONOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL (submitted in 2019)
	5PSQ-041	CONSUMPTION OF HERBAL MEDICINE IN PATIENTS ON ORAL ANTICANCER DRUGS: STILL A LONG WAY TO GO! (submitted in 2019)
	5PSQ-042	EVALUATION OF AN INFORMATION CHECKLIST FOR VALIDATION OF ANTINEOPLASTIC PRESCRIPTIONS (submitted in 2019)
	5PSQ-043	IMPLEMENTATION OF A PREPARATION PROTOCOL FOR CHEMOTHERAPY ADMIXTURES OF HIGH ECONOMIC IMPACT (submitted in 2019)
	5PSQ-044	IMPACT OF DRUG INTERACTIONS IN HIGH DOSE METHOTREXATE ELIMINATION (submitted in 2019)
	5PSQ-045	OLARATUMAB: WHAT IS THE ECONOMIC IMPACT ON THE NATIONAL HEALTH SYSTEM? (submitted in 2019)
	5PSQ-046	PREVALENCE OF NIVOLUMAB ADVERSE EVENTS IN ROUTINE CLINICAL PRACTICE (submitted in 2019)
	5PSQ-047	RIBOCICLIB SAFETY IN METASTATIC BREAST CANCER (submitted in 2019)
	5PSQ-048	ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ANTINEOPLASTIC AGENTS AND CONCURRENT MEDICATIONS (submitted in 2019)
	5PSQ-049	PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: REAL LIFE TOXICITY AND FREQUENCY OF DOSE REDUCTION OR PERMANENT DISCONTINUATION. (submitted in 2019)
	5PSQ-050	SUCCESSFUL DESENSITISATION IN A PATIENT WITH DASATINIB HYPERSENSITIVITY (submitted in 2019)
	5PSQ-051	IMMUNE RELATED ADVERSE EVENTS IN CANCER PATIENTS TREATED WITH CONTROL POINT INHIBITORS (submitted in 2019)
	5PSQ-052	EARLY RESULTS FROM THE EFFECTIVENESS AND SAFETY EVALUATION OF BIOSIMILAR RITUXIMAB AND BRAND-RITUXIMAB IN GLOMERULAR INFLAMMATORY DISEASE (submitted in 2019)
	5PSQ-053	OFF-LABEL USE OF RITUXIMAB IN SYSTEMIC AUTOIMMUNE DISEASES (submitted in 2019)
	5PSQ-054	EXAMINATION OF A NEW METHOD FOR ANALYSING IDENTITY AND CONCENTRATION OF DRUGS IN READY TO USE PREPARATIONS: PROOF OF CONCEPTS OF THE DRUGLOG SYSTEM (submitted in 2019)
	5PSQ-055	FILGRASTIM IN EARLY STAGE BREAST CANCER: DIFFERENCES BETWEEN TWO SMALL HOSPITALS (submitted in 2019)
	5PSQ-056	EXPERIENCE WITH TOFACINITIB AND BARICITINIB IN RHEUMATOID ARTHRITIS (submitted in 2019)
	5PSQ-057	ANALYSIS OF INCIDENCE OF HEPATOTOXICITY ASSOCIATED WITH THE USE OF TOCILIZUMAB (submitted in 2019)
	5PSQ-058	THE IMPORTANCE OF MONITORING ADVERSE DRUG REACTIONS: DATA FROM THE TREATMENT OF A RARE DISEASE (submitted in 2019)
	5PSQ-059	PHARMACIST-LED OBSERVATIONAL STUDY ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: EVIDENCES FROM THE QOSMOS STUDY (submitted in 2019)
	5PSQ-060	EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN CLINICAL PRACTICE FOR CROHN'S DISEASE (submitted in 2019)
	5PSQ-061	ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: EFFECTIVENESS AND SAFETY (submitted in 2019)
	5PSQ-062	EFFECTIVENESS OF ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE AND INFLUENCE OF RESPONSE TO FIRSTLINE TREATMENT (submitted in 2019)
	5PSQ-063	SERIOUS CELLULITIS IN A PATIENT WITH ATOPIC DERMATITIS TREATED WITH BARICITINIB: A CASE REPORT (submitted in 2019)
	5PSQ-064	RELATED RISK OF BIOLOGIC DRUGS FOR CROHN’S DISEASE IN PREGNANCY: A CASE REPORT AND REVISION OF THE LITERATURE (submitted in 2019)
	5PSQ-065	PREDICTION OF TOXICITY OF METHOTREXATE BY MEANS OF GENETIC TESTS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS (submitted in 2019)
	5PSQ-066	ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN ELDERLY ONCOLOGIC PATIENTS BY THE CHECK THE MEDS APP (submitted in 2019)